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Background: Fibromyalgia (FM) is characterized by chronic diffuse pain, fatigue, 
memory problems, sleep disturbance, depression, and mobility limitations. The 
Department of Defense (DoD) and Department of Veterans Health Administration (VA) 
recognize FM as potentially connected to service in the Persian Gulf War, and the rates of 
FM diagnosis and disability in the VA are rising. 
Purpose: The purpose of this dissertation was to assess the feasibility and acceptability 
of heart rate variability biofeedback (HRVB) as an intervention for the treatment of FM 
in Veterans.  
Problem/Aims: We conducted an integrative literature review (manuscript 1) and 
identified a gap in the literature related to HRVB to treat FM-related chronic pain. 
Overall, HRVB is a promising treatment for chronic pain; however, further research is 
needed to evaluate the relationship between HRVB and FM pain. We found only one 
study evaluating HRVB for the treatment of FM, and we did not identify any studies that 
evaluated the recommended HRVB practice protocols, or any qualitative studies 
investigating the individual experience of using HRVB. The specific aims of this 
dissertation were: 
Aim 1: Examine the feasibility of recruitment and retention of Veterans with 
fibromyalgia. 
Aim 2: Determine the feasibility of adherence to the recommended HRVB 
practice protocol using the emWave2. 




Design: We used a sequential exploratory multi-method design to determine if it is 
feasible for Veterans with FM to follow a twice-daily 20-minute HRVB practice 
protocol. We conducted a focus group post-intervention to explore the participant’s 
experiences with HRVB. 
Theoretical framework: The theory of symptom self-management guided the study; it 
posits that when self-directed interventions are optimized, performance outcomes will 
improve. 
Findings: We found that it was not feasible for Veterans with FM to follow the 
recommended HRVB protocol. Barriers identified were conflicts with family obligations 
and work schedule as well as difficulties operating the HRVB device. Results from 
weekly questionnaires suggested an improvement in functional status and quality of life, 
but no change in pain levels. However, during the focus group discussion, the Veterans 
reported a reduction in pain levels as well as improvement in sleep, relaxation, and 
cognition. 
Conclusion: Limitations of this study were a small size (n=10), possible self-selection 
bias, and the lack of a control group. While the data suggests HRVB may improve the 
functional status and quality of life of those with FM, more research is needed.  
Keywords: fibromyalgia, chronic pain, heart rate variability biofeedback, veterans, 
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 Fibromyalgia (FM), a complex chronic pain syndrome, affects 10 million 
individuals in the United States (1, 2). The associated fatigue, memory problems, sleep 
disturbance, depression, anxiety, cognitive impairment, and mobility limitations (2, 3) 
contribute to 1-2% loss of national productivity (4, 5), $12-14 billion per year in national 
health care costs (4), and individual deficits in quality of life (6).  
FM is recognized by the Department of Defense (DoD) and Department of 
Veterans Health Administration (VA) as potentially connected to service in the Persian 
Gulf War (7). The DoD and VA have linked FM to the physical and emotional trauma 
sustained by service members who deployed during the war as well as to the various 
natural and man-made environmental exposures in that region (8). Repetitive muscular 
injuries are attributed to service members carrying over 80 pounds of equipment daily for 
6-12 months, during multiple deployments between October 2001 and the present; this 
has resulted in more than 50% of service members/Veterans returning from these 
conflicts reporting chronic pain not related to direct injuries such as shrapnel, gun shots, 
or blasts (8-10). The rate of diagnosis and disability of Veterans is rising at an alarming 
rate (11). With ongoing conflicts around the world, we do not expect the rate of FM cases 
to decrease. As health care providers in the VA it is our mission to fulfill President 
Lincoln’s promise “to care for him who shall have borne the battle”(12), and to honor the 
VA core value of excellence by striving for the highest quality and continuous 
improvement in care. Thus, we chose to focus our study on the Veteran population, 




 Because of the complexity of symptoms reported by individuals with FM, and the 
unclear etiology of the disease, primary care physicians and advanced practice nurses 
have had difficulty diagnosing and treating these patients. The diagnostic criteria for FM 
have changed significantly in recent years. The initial diagnostic criteria set by the 
American College of Rheumatology (ACR) in 1990 was determined by the number of 
“tender points” reported by the patient during a time-consuming, complex physical exam 
(13). In 2010 the ACR determined that 25% of patients with FM did not meet the 
“tender-point” test of FM and modified the survey to address the associated fatigue, 
sleep, and cognitive changes (2). “Tender-points” are subjective reports of pain or 
discomfort when the practitioner applies pressure specified areas of the head, neck, chest, 
back, and extremities (2). FM diagnosis was satisfied with one of the following 3 
conditions: 1) the Widespread Pain Index (WPI) ≥ 7, the Symptom Severity Score (SS) ≥ 
5, or the WPI = 36 and the SS ≥ 9; 2) symptoms present and at a similar level for at least 
3 months, or 3) the patient lacked a disorder that would otherwise explain the pain (2). 
The initial survey was self-administered by the patient and then completed by the 
physician after a physical exam. Wolfe et al. (14) developed a modification of the 2010 
criteria that allows complete self-administration by the patient. Primary care physicians 
and advanced practice nurses can give the survey to patients and easily interpret the 
results without a visit to a specialist, such as a rheumatologist. The developers argue this 
practice could decrease time to diagnosis and treatment (14). Additionally, the modified 
survey identifies a higher FM prevalence and a larger proportion of men with FM (15). 
The diagnostic sensitivity to men in the modified survey may explain the increased rate 




 Individuals with FM often report symptoms that are variable and unpredictable, 
leading to frustrations around reporting their symptoms and often feeling as if the health 
care provider does not believe them (16, 17). Individuals with FM are also frustrated by 
the lack of clarity of a diagnosis, which leads to skepticism from family, friends, and 
health care professionals(16). Additionally, patients reported they are often given very 
little if any information about FM by their health care provider, and have to seek answers 
from other patients, support groups, or family members with the same diagnosis (17). FM 
patients are often skeptical of treatment recommendations, especially medications, 
because prescribing physicians have difficulty explaining how the treatment will target 
their symptoms or disease (17). FM patients report they are often better understood and 
receive more acceptable treatment from holistic providers; however, these treatments are 
often not covered by health insurance plans (16).  
Treatment Recommendations 
Health care providers agree that symptoms associated with FM are generally not 
demonstrated in chronic headaches, back, joint, or neck pain; thus, comparing treatment 
among these pain syndromes is challenging (2, 6). The VA/DoD has published clinical 
guidelines for chronic pain management (18). The most common published guidelines for 
FM treatment are from the European League Against Rheumatism (EULAR) 2016; the 
American Pain Society (APS) 2005; the German Association of the Scientific Medical 
Societies (AWMF) 2013; the Israeli Pain Society (IPS); and the Canadian Pain Society 
(CPS) (15, 19). Recent research and findings of the etiology and pathophysiology of FM 
indicate treatment must be multi-focal (15). There is a consensus among the EULAR, 




multidisciplinary approach that prioritizes nonpharmacological treatments, offers 
judicious pharmacological treatments (15, 19), and are based on the biopsychosocial 
model (15).  
Pharmacological therapies. Pharmacological treatment guidelines vary greatly, 
which increases the difficulty in treating FM. VA/DoD treatment guidelines recommend 
against the use of opioids to treat FM-related chronic pain (18). EULAR and AWMF do 
not recommend common non-opioid analgesic treatments such as non-steroidal anti-
inflammatories (NSAID) (20). There is no evidence for the effective use of 
acetaminophen or topical creams/ointments (1, 15, 21). Importantly, AWMF and EULAR 
strongly recommend against the use of opioids (15, 21). The published World Health 
Organization pain ladder includes opioids. However, it was designed for chronic pain 
related to cancer and is not appropriate for the treatment of widespread chronic pain as is 
seen in FM (15). The antidepressant amitriptyline has some evidence for both the 
treatment of neuropathic pain and sleep disturbance and received varying 
recommendations from all four guidelines (15). CPS guidelines recommend gabapentin 
and pregabalin, although EULAR gives them a weak recommendation, and AWMF 
recommends the use of pregabalin only if the use of amitriptyline is not possible, and 
does not make any decision about gabapentin (21). AWMF, CPS, and EULAR 
recommend serotonin-norepinephrine uptake inhibitors (SNRI) like duloxetine, which 
may provide some benefit (21). Milnacipran, a newer SNRI, is only recommended in the 
EULAR guidelines and not recommended in the AWMF guidelines (21).  
Nonpharmacological therapies. All treatment guidelines agree that FM 




analysis of randomized controlled trials examining the effects of exercise on FM 
symptoms of fatigue, physical functioning, depression, and quality of life support this 
recommendation (22). All guidelines except EULAR include psychological treatment that 
includes cognitive behavior therapy a “strong recommendation” (15, 19, 20). 
Complementary and alternative medicines (CAM) like acupuncture, Tai Qi, and 
chiropractic treatments are controversial but encouraged in the CPS guidelines (15). 
Currently, however, there is insufficient evidence to support the use of CAM (15). The 
most recent VA/DoD Clinical Practice Guidelines for the treatment of chronic pain, 
which includes pain related to fibromyalgia, is to utilize cognitive behavior therapy, 
biofeedback, exercise, multidisciplinary psychosocial rehabilitation (3, 18), physical 
therapy, occupational therapy, acupuncture, manipulation, and CAM (9, 15). 
EULAR treatment guidelines only evaluated two reviews that included biofeedback as a 
treatment for FM (20). EULAR committee members do not recommend biofeedback, 
because while it is effective in reducing pain intensity it is not effective for fatigue or 
sleep (20). The report did not specify the type of biofeedback evaluated.  
Pathophysiology of FM 
 The symptoms of FM - fatigue, memory problems, sleep disturbance, depression, 
anxiety, and cognitive impairment - are complex, and the above-referenced treatment 
recommendations do not address recent findings of the etiology of FM (23, 24). Research 
utilizing functional magnetic resonance imaging (fMRI) demonstrates that in individuals 
with FM, there is a disruption of pain network connectivity. Strengthened connectivity of 
the brain regions involved in the processing and reduced connectivity of the regions 




The default mode network (DMN), a constellation of brain regions engaged in 
self-referential thinking, is disrupted in FM during tasks like visual attention and 
cognitive attention, which may explain symptoms of memory problems and cognitive 
impairment (24). An abnormally increased level of connectivity between the DMN and 
the insular cortex may also explain higher reported pain levels (25). Additionally, a 
dysfunction of the cardiac autonomic nervous system (ANS), characterized by higher 
sympathetic and lower parasympathetic cardiac autonomic modulation, is associated with 
incoherent heart rate variability and is related to the impact of FM on quality of life (6, 
26).  
Heart Rate Variability 
Heart rate variability (HRV) is the time measurement of the oscillations of the R-
to-R intervals (27-29) (see Figure 1). HRV reflects heart-brain interaction and ANS 
function (28-31) and HRV information on how the ANS interacts and functions as a 
whole (32). Analyzing HRV provides quantitative information about the state of the ANS 
(6). 
 
Figure 1. Heart rate variability  
Optimal HRV is cardiac coherence, a sine-waveform that is ordered and harmonic 
(33). Coherent HRV reflects a healthy functioning system, adequate physical functioning, 
minimal pain (28), resistance to stress, emotional adaptability (27), and self-regulation 
(33) (see Figure 2). Conversely, an HRV measurement that is too little or chaotic is 




contributing to chronic pain, decreased physical functioning, and poor quality of life (6, 
28, 31).  
 
Figure 2. Heart rate variability waveform 
Image retrieved from heartitelligence.com 
With current technology, we can obtain HRV measurements non-invasively from 
an electrocardiogram, pulse wave recordings, or a plethysmographic optical sensor placed 
at the fingertip or on the earlobe (32). Devices that measure HRV using the fingertip or 
earlobe sensor are easily used by professionals and non-specialists, are relatively 
inexpensive, and can be used in the clinical setting as an educational tool for patients or 
by patients at home to regulate emotional states, stress resistance, and quality of life (32).  
Heart Rate Variability Biofeedback 
 Heart rate variability biofeedback (HRVB) (34) is an innovative, non-
pharmacological self-management strategy that uses technology to induce a vagal 
response as the individual slows their breathing rate to 4-6 breaths per minute (33). This 
technologically-guided breathing produces a maximized respiratory sinus arrhythmia, a 
coherent HRV (34). HRVB has the potential to improve emotion regulation, stress 
resistance (35-37), and quality of life (33, 37, 38). Repeated sessions of HRVB can 
sustain improved HRV coherence for longer periods and, with sufficient practice, can be 




stress resistance and emotional adaptability to decrease pain and increase overall well-
being (33, 35, 37).  
Lehrer et al. (39) determined individuals cannot simply achieve and sustain an 
optimal breathing rate to reach HRV coherence without training with the developed 
HRVB protocols. HRVB training must occur gradually to adjust to the decreased rate of 
breathing of 4 to 6 breaths per minute (40). The emWave2 is a handheld visual HRVB 
device. It is easy to use and available on the general market. A photoplethysmograph 
(PPG) sensor is clipped on the participant’s ear and connected to the device. A blinking 
blue light on the device indicates the device is reading the individual’s pulse (41). The 
strip of light fluctuates between red, blue, and green as the individual breathes 
rhythmically (see Figure 3). The individual is instructed to take slow, rhythmic breaths. 
The goal is to increase HRC and change the coherence level indicator from red (low 
coherence/baseline) to blue (medium coherence/improving) to green (high 
coherence/optimal), and to remain in the green zone as long as possible during the 
practice session (41). A trained registered nurse (RN) can teach a patient HRVB during a 
routine primary care visit, thus allowing nurse practitioners and physicians time for 











 We conducted an integrative literature review to examine the relationship between 
HRVB and FM-related pain. We found six studies that examined the relationship 
between HRVB and chronic pain; only one of the studies examined FM-related pain. 
HRVB is a promising, effective treatment modality for chronic back pain, joint pain, neck 
pain, and headaches. As stated earlier, FM-related pain is complex and includes 
symptoms not usually seen in chronic headaches or musculoskeletal pain, and thus, 
treatment cannot be the same. We identified that although incoherent HRV is associated 
with FM-related symptoms, such as pain, mood disturbance, and fatigue, and coherent 
HRV is associated with normal physical function, stress resistance, and emotional 
stability, there is a lack of research investigating HRVB to treat FM-related chronic pain. 
Theoretical Foundation 
The primary complaints from those suffering from FM are symptoms of diffuse 
pain, fatigue, changes in mood, sleep deprivation, and brain fog (15). The Theory of 
Symptom Self-Management (TSSM) has been used to assist individuals in reducing, 
preventing, relieving, or decreasing the frequency of unpleasant symptoms like those 
experienced in FM, through self-management-enhancing interventions (SMI) (42, 43) 
like HRVB (33, 38, 44). The central tenet of TSSM that guided this study is that by 
optimizing self-directed SMI, such as HRVB, performance outcomes will improve.  
The key concepts of TSSM are: 1) perceived self-efficacy for symptom self-management 




performance outcomes, and 6) perceived self-efficacy-enhancing interventions (PSI) (43). 
Figure 4 has been modified to illustrate the application of TSSM to HRVB. 
 
Figure 4. Theory of Symptom Self-Management model to HRVB (43) 
PSM is the confidence or belief of one’s own ability to implement or execute specific 
behaviors to attain established goals or desired outcomes (43). We asked participants if 
they believed HRVB would be an effective treatment before starting the study. We also 
asked if they believed they were successful with the prescribed protocol and if they 
believed they were able to affect change in their symptoms. 
PSI includes self-management skills that support self-efficacy and improve self-
care (43). Participants in this study implemented HRVB to self-manage their FM-related 
chronic pain. The participants evaluated the skill level of their self-management by 
reading the output (light display) on the emWave2 device and adjusted their breathing 
rate until they reached their goal of “green light.” 
Symptom self-management encompasses self-directed active behaviors that may 
identify, prevent, and relieve or decrease the timing, intensity, and distress of symptoms 




recommendations by Lehrer et al. (39) and encouraged the participants to practice HRVB 
for 20 minutes, twice daily. The participants had immediate feedback regarding optimal 
use from the red, blue, and green display lights. Additionally, we reviewed the prior week 
practice schedule with the participant and helped them identify any barriers to the 
recommended practice schedules. 
Performance outcomes are the effects of the individual’s symptom self-
management experience (43). The goal of HRVB is to decrease symptoms of pain, 
depression, fatigue, and improve cognitive and physical function. These symptoms have a 
direct effect on the performance outcomes of quality of life and functional status. 
Methodology 
We used a sequential exploratory multi-method design to assess the feasibility 
and acceptability of HRVB as a treatment for FM. We conducted eight individual weekly 
HRVB training sessions. We guided the participants’ practice of HRVB breathing 
techniques for 20 minutes during each weekly session.  
During each weekly session, we also collected and evaluated quantitative 
physiological data provided by the HRVB device each time the participant practiced. We 
collected psychometric data from the Short Form McGill Pain Questionnaire (SFMQ) 
and measured performance outcomes of functional status and quality of life from the 
Revised Fibromyalgia Impact Questionnaire (FIQR). We collected quantitative data 
about the acceptability of HRVB using the Credibility/Expectancy Questionnaire (CEQ). 
Data from the CEQ was used to explain the qualitative results obtained from focus group-
driven open-ended questions post-intervention. We evaluated PSM, the Veteran’s ability 




evaluated PSI through the physiological measurement of HRV coherence from the 
emWave2 device, as well as participant reports during the focus group discussions about 
the personal experience of HRVB. 
Manuscripts 
 This dissertation consists of three manuscripts. The first manuscript, an 
integrative literature review, examined the relationship between HRVB and FM-related 
chronic pain using the Theory of Symptom Self-Management. The relationship between 
HRVB and FM was analyzed and evaluated based on the methodological framework 
proposed by Whittemore and Knafl (45). Overall the articles in this review support that 
HRVB is related to decreased pain. HRVB is a promising effective treatment for chronic 
pain. However, larger randomized controlled studies are needed to evaluate the 
relationship between HRVB and FM pain thoroughly.  
The second manuscript details a multi-method study that examined the feasibility 
of recruitment and retention of Veterans with FM. We provided quantitative data from 
the emWave2 HRVB device about the feasibility of the HRVB protocol recommended by 
Lehrer et al. (39). We also reported outcomes related to quality of life from the FIQR, 
pain from the SFMQ, and HRV changes pre-and-post intervention. 
The third manuscript is a qualitative report of the post-intervention focus group. 
Eight of the ten enrolled Veterans participated in the focus group. The participants 
provided rich data about their experience with HRVB, their expectations before the 
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Objectives: Fibromyalgia (FM) is associated with debilitating pain and a reduced heart rate variability
(HRV), reflecting decreased emotional adaptability and resistance to stress. Common pharmacological
treatments are ineffective, and opioids are highly addictive and cause an estimated 15,000 overdose
deaths per year. Effective recommendations include patient-centered interventions like physical activity,
cognitive behavioral therapy, and biofeedback. Heart rate variability biofeedback (HRVB) may be effective
in improving HRV, thus increasing stress resistance and emotional adaptability and reducing pain.
Design: This integrative literature review was conducted to examine the relationship between HRVB and
FM-related chronic pain using the Theory of Symptom Self-Management and to identify available HRVB
technology.
Data Sources: We searched PubMed, EBSCOhost, and Google Scholar electronic databases for relevant
publications. Manuscripts were selected using the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses strategy, and study quality was assessed using the Critical Appraisal Skills Programme
guidelines. The relationship between HRVB and FM was analyzed and evaluated based on the meth-
odological framework proposed by Whittemore and Knafl.
Review/Analysis Methods: We reviewed 22 articles and included six in this review. Five reported HRVB as
a treatment for chronic pain, and one for FM pain.
Results: Overall, the articles in this review support the claim that HRVB is related to decreased pain. The
researchers evaluated five HRVB programs, three on handheld devices and two on desktop computers.
Conclusions: The reviewed studies had methodological flaws. However, HRVB is a promising treatment
for chronic pain. Larger, randomized controlled studies are needed to thoroughly evaluate the rela-
tionship between HRVB and FM pain.
Published by Elsevier Inc. on behalf of the American Society for Pain Management Nursing
Fibromyalgia (FM), a complex chronic pain syndrome, affects 10
million individuals in the United States (Center for Disease Control,
2017). Unlike other chronic pain-related conditions, FM involves an
incoherent heart rate variability (HRV) and a dysfunctional auto-
nomic nervous system (ANS) (Cohen et al., 2000; Dworkin & Fields,
2005; Martínez-Lavín& Hermosillo, 2000). HRV, the change in time
intervals between heartbeats, reflects heartebrain interaction and
ANS function (Cho et al., 2011; Kang, Chen, Chen,& Jaw, 2012;Meeus
et al., 2013; Mostoufi, Afari, Ahumada, Reis, & Wetherell, 2012).
When HRV is incoherent, chaotic, or insufficient, ANS is also
dysfunctional, contributing to the chronic pain, decreased physical
functioning, and poor quality of life that are associated with fibro-
myalgia (Cohen et al., 2000; Kang et al., 2012; Meeus et al., 2013).
Optimal or coherent HRV is associated with improved physical
functioning, improved stress regulation, improved emotional
arousal, and improved stress resistance (De jonckheere, Ibarissene,
Flocteil, & Logier, 2014; Kapitza, Passie, Bernateck, & Karst, 2010;
Lehrer & Gevirtz, 2014; McCraty & Shaffer, 2015).
Heart rate variability biofeedback (HRVB), a form of cardiore-
spiratory feedback training (Lehrer & Gevirtz, 2014), is a self-
management strategy that induces a vagal response as the individ-
ual slows their breathing rate to 4-6 breaths per minute (McCraty&
Shaffer, 2015). The decreased rate of breathing during HRVB will
induce a slower heart rate, allowing more time between heartbeats
and an improvement in HRV coherence (McCraty & Shaffer, 2015).
Additionally, repeated sessions of HRVB can sustain HRV coherence
for longer periods of time (McCraty & Shaffer, 2015). It is hypothe-
sized that routine use of HRVB can decrease pain, improve stress
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resistance and emotional adaptability, and increase overall well-
being (Cohen et al., 2000; McCraty & Shaffer, 2015).
The purpose of this integrative literature reviewwas to examine
studies that reported on the relationship between HRVB and FM-
related chronic pain using the Theory of Symptom Self-
Management as the theoretical framework. Additionally, we
sought to identify which HRVB technology has been used and any
comparisons amongdevices. However,wewere able to identify only
one study devoted solely to FM-related chronic pain. To fully eval-
uate HRVB as a treatment for pain, we included other forms of
chronic pain in our literature review.
Theoretical Framework
The Theory of Symptom Self-Management (TSSM) has been used
to assist individuals to reduce, prevent, relieve, or decrease the
timing of unpleasant symptoms, such as chronic pain, through self-
management-enhancing interventions (Fu, LeMone, & McDaniel,
2004; Hoffman, 2013), such as biofeedback (Burckhardt, 2004;
Vancleef, 2011) and HRVB (McCraty & Shaffer, 2015; Moss &
Shaffer, 2017; Wheat & Larkin, 2010). The central tenet of TSSM
that guided this review is that functional and cognitive performance
outcomes, such as quality of life and functional status, are improved
by optimizing self-directed, self-management, perceived self-
efficacy (PSE)eenhancing interventions, such as HRVB (Hoffman,
2013; Lorig & Holman, 2003). The key concepts of TSSM are as fol-
lows: 1) PSE for symptomself-management, 2) actual symptomself-
management, 3) patient characteristics, 4) symptoms, 5) perfor-
manceoutcomesandPSE-enhancing interventions (Hoffman, 2013).
Perceived Self-Efficacy for Symptom Self-Management
Self-efficacy influences how a person thinks, feels, motivates
him- or herself, and performs actions (Bandura, 1994). PSE is the
belief or confidence one has in oneself to perform or execute the
actions required to produce the desired effects or outcomes
(Bandura, 1994). PSE for symptom self-management is a patient's
ability to implement specific behaviors to attain established treat-
ment goals or desired outcomes (Hoffman, 2013).
Symptom Self-Management
Symptom self-management encompasses self-directed active
behaviors that may prevent or relieve symptoms such as pain or
decrease their frequency or intensity, allowing the patient to reach
optimal performance outcomes (Hoffman, 2013). Self-management
with biofeedback has been shown to be an effective treatment for
FM pain (Macfarlane et al., 2017). The symptom self-management
behaviors analyzed in this review are the consistent and correct
use of biofeedback. Use is considered correct if the patient engages
in HRVB as often and for as long as prescribed, following the pre-
scribed breathing rate and depth while following along with the
electronic signals emitted by the feedback device.
Patient Characteristics
Patient characteristics include the physiological and psycholog-
ical factors that influence outcomes and may include severity of
illness, comorbidities, age, mental state or mood status, personal
beliefs, affective reaction to illness or disease, and degrees of un-
certainty (Hoffman, 2013). The patient physiological and psycho-
logical characteristics analyzed in this review are mental health
status, sleeping difficulties, gender, marital status, and employment
status. Depression and mood disturbance, commonly seen in FM
(Cohen, 2017; Macfarlane et al., 2017), are significant factors in pain
management and are influencing factors on self-management (Fu
et al., 2004). Fatigue or unrefreshing sleep is a hallmark symptom
of FM (Wolfe et al., 2010) and can also greatly influence self-
management (Cohen, 2017; Fu et al., 2004; Rosso & Maddali-
Bongi, 2016). Work absenteeism and disability are considered the
cause of an average of 26% of the indirect costs associated with FM
and 42% of the costs of unemployment owing to FM disability
(Chandran et al., 2012; Ghavidel-Parsa, Bidari, Amir Maafi, & Gha-
lebaghi, 2015; Schaefer et al., 2015). Women comprise 86%-96% of
the population of FM patients and have a higher divorce rate when
compared to those suffering from other chronic pain diseases
(Wolfe, Ross, & Anderson, 1995).
Symptoms
Symptoms are the subjective experiences of a perceived threat to
health orwellness, or are signs of an undesirable outcome (Hoffman,
2013). Symptoms of FM can be diffuse and multifocal, and they can
wax and wane daily. The symptoms analyzed in this review are
chronic pain, fatigue, depression, and low HRV. FM-related pain is
often characterized as a widespread ache with multiple diffuse,
exquisitely tender muscle points (Wolfe et al., 2010).
Performance Outcomes
Performance outcomes are the effects of a person's symptom
self-management experience (Hoffman, 2013). Desired outcomes of
self-directed behaviors, such as HRVB, include decreased symptoms
of pain, depression, and fatigue, less symptom distress, and fewer
symptom occurrences (Fu et al., 2004; Hoffman, 2013). These out-
comes have a direct effect on quality of life (Cohen, 2017; Fu et al.,
2004; Macfarlane et al., 2017), sleep (Cohen, 2017; Rosso &
Maddali-Bongi, 2016), and functional status (Cohen, 2017). The
performance outcomes analyzed in this review are functional sta-
tus and quality of life.
Perceived Self-EfficacyeEnhancing Interventions
A patient's ability to perform PSE-enhancing interventions is
developed through activity performance along with social or verbal
persuasion by others, which determines how the individual will
think, feel, self-motivate, andperform (Hoffman, 2013). Thebuilding
blocks of PSE-enhancing interventions include mastery of the ac-
tivity byperforming it oneself, observing others perform the activity
successfully, being persuaded by others that the activity is possible,
and perceiving one's self as possessing the strength to achieve the
goal (Hoffman, 2013). The following were analyzed in this review:
mastery of HRVB skills via observation of trainers and frequently
performing the skill oneself, being socially persuaded to perform




This integrative review was guided by the methodological
framework proposed byWhittemore& Knafl (2005). The five stages
include 1) identifying a gap in the literature about HRVB as a
treatment for FM-related chronic pain, 2) searching in the literature
for studies supporting the use of HRVB to treat FM, 3) evaluating
data using the Critical Appraisal Skills Programme (CASP) scoring
system, 4) analyzing data using the TSSM as a framework, and 5)
visually presenting a review matrix (Whittemore & Knafl, 2005).
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Search Methods
In September 2017, a reference librarian at an academic medical
center was consulted to assist in finding the most appropriate
approach in searching the literature for applicable studies. The
literature was systematically selected to be included in the sample
using the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (see Fig. 1). We searched PubMed, EBSCOhost, and
Google Scholar electronic databases for relevant publications. We
searched each database for the following terms: [heart rate vari-
ability OR heart rate variability biofeedback OR heart rate coherence
biofeedback OR heart rate coherence OR biofeedback] AND [fibro-
myalgia] AND [chronic pain]. The terms evolved from concept maps
used in the development of the aims of this review. We included
primary studies of any research design in the review. We reviewed
reference lists from included manuscripts to identify literature not
found in the initial database searches manually.
The original planned study inclusion criteria were: 1) articles
that included fibromyalgia pain in the outcome measures, 2) arti-
cles reporting HRVB as an intervention, 3) peer-reviewed articles in
the English language, and 4) adult participants (>17 years). Exclu-
sion criteria were: 1) non-FM pain, 2) literature reviews, and 3)
non-HRVB biofeedback. This search returned only one study. The
search criteria were expanded to include other forms of chronic
pain. During the review, studies involving cancer pain were elimi-
nated; this search yielded 21 more studies. We did not set a time
limit because of the novelty of the subject matter as well as an
interest in historical findings.
Search Outcomes
The initial database searches yielded 22 articles. We removed 10
duplicates and reviewed the full text of the remaining 12 articles.
Three of the articles eliminated were literature reviews of HRVB
(Gevirtz, 2013; Moss & Shaffer, 2017; Wheat & Larkin, 2010); these
were hand-searched for original studies. However, no additional
studies met inclusion criteria.
The remaining nine full-text articles were then further
assessed for eligibility, yielding six studies. Two of the articles
eliminated reported HRVB findings, but not pain treatment
(Edwards, 2014; Whited, Larkin, & Whited, 2014). The final one
eliminated was an explanatory paper on how and why HRVB
works (Lehrer & Gevirtz, 2014). A review of reference lists of the
selected articles and the previous literature reviews did not yield
any additional studies.
Data Presentation
The resulting data were categorized and presented in table form
(Table 1) by reference, interventions, biofeedback technology,
population, study design, outcomemeasures, relevant findings, and
grading. The Critical Appraisal Skills Programme (CASP) guided the
grading of each randomized controlled and cohort study by
addressing three broad questions: 1) Are the results of the study
valid? 2) What are the results? and 3) Will the results help locally?
(Critical Appraisal Skills Programme, 2018).
Results
Overview of Studies
The six articles reviewed consisted of three randomized pilot
studies (Berry et al., 2014; Hallman, Olsson, von Scheele, Melin, &
Lyskov, 2011; Weeks, Whitney, Tindall, & Carter, 2015) one non-
randomized pilot study (Hassett et al., 2007), one retrospective
archival study, (Wilson, 2017), and one retrospective cohort study
(Soer, Vos, Hofstra, & Reneman, 2014). The independent variable
was HRVB in all studies. The study by Hassett et al. (2007) was the
only one which treated FM-related pain solely with HRVB. Hallman
et al. (2011) compared two forms of treatment for neck and
shoulder pain. Patients in the first group received multiple sessions
of HRVB, whereas those in the second group received the same
breathing protocol instructions during session one but did not
receive instructions on breathing during the remaining sessions.
Berry et al. (2014) added HRVB to standard care for chronic pain;
however, they did not specify what this care entailed or specifics
about pain location. However, they did exclude individuals with
diabetes or traumatic musculoskeletal system damage. Soer et al.
(2014) added HRVB to Back School, a personalized pain rehabili-
tation program designed to increase physical capacity and cognitive
behavior interventions for chronic back pain. Weeks et al. (2015)
compared faded HRVB to full HRVB in nine sessions to treat non-
malignant chronic musculoskeletal pain, fibromyalgia, headache,
neuropathy, and reflex sympathetic dystrophy over a 3-week
period. Faded HRVB consisted of visual feedback during session 1,
followed by a systematic reduction of visual biofeedback with each
session so that by session nine, the participants were controlling
HRV without visual feedback. The control group received visual
biofeedback for nine sessions. Wilson (2017) included individuals
with neuropathic pain, musculoskeletal pain, and headache. The
primary outcomes measured were pain (n ¼ 6), functional status
(n ¼ 5), depression (n ¼ 3), HRV (n ¼ 4), catastrophizing (n ¼ 1),
sleep (n ¼ 1), anxiety (n ¼ 1), somatization (n ¼ 1), self-reported
health status (n ¼ 1), and biofeedback skills (n ¼ 1). Only three
studies reported study controls: standard care (n ¼ 1), Back School
(n ¼ 1), and full HRVB (n ¼ 1). Although none of the studies or
reviews articulated the use of any theoretical framework or model,
























Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Statement
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The participants in all studies were instructed and coached by
HRVB-trained clinicians or researchers on how to correctly use the
respective HRVB device (Hallman et al., 2011; Hassett et al., 2007;
Soer et al., 2014; Weeks et al., 2015; Wilson, 2017). The authors did
not indicate how these instructions affected the study outcomes.
Frequency
The participants practiced HRVB in weekly sessions that ranged
from 10 weeks (n ¼ 2) to 6, 5, and 3 weeks (Berry et al., 2014;
Table 1
HRVB Literature Review Outcomes
Reference Intervention Biofeedback
Technology
Population Design Outcome Measures Relevant Findings CASP Score
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BF ¼ biofeedback; F ¼ female; HRV ¼ heart rate variability; HRVB ¼ heart rate variability biofeedback; M ¼ male; T ¼ transgender.
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Hallman et al., 2011; Hassett et al., 2007; Soer et al., 2014; Weeks
et al., 2015; Wilson, 2017). Sessions lengths varied, ranging from
10minutes (n¼ 2) to 20minutes (n¼ 1) to 45-60minutes (n¼ 1) to
a full hour (n ¼ 1). Berry et al. (2014) did not provide the length of
time per session. Hassett et al. (2007) and Hallman et al. (2011)
added recommendations for daily home practice, 20 minutes
twice daily and 15 minutes 5 times a week, respectively.
Verbal or Social Persuasion
Hassett et al. (2007) and Wilson (2017) reported additional
verbal coaching to improve respiration rates and prevent partici-
pant hyperventilation. None of the study participants had the op-
portunity to observe their peers using HRVB.
Self-Interpretation of HRVB Skills
PSE can be enhanced when individuals are able to self-interpret
skill mastery. All the HRVB devices reviewed provided visual feed-
back that allowed the participants to track HRV coherence while
they breathed at the prescribed rate and depth. The Relaxing
Rhythms training program displayed an image of a staircase on a
screenwhen HRV was coherent and disappeared when incoherent;
as the participant advanced in skill level and continuedwith optimal
HRV, the staircase evolved into a bridge (Wilson, 2017). Blinking
lights advanced from red (no synchronization) to blue (advancing
synchronization) to green (optimal synchronization) on the emWave
desktop HRVB program (Heart Math, 2004). The J&J I-330 HRVB
device projected a light display onto a computer screen that moved
upas the target respiratory frequencywasachieved, anddownas the
target was lost (J&J Engineering). Only Soer et al. (2014) reported
that the participants were required to demonstrate basic HRVB skill
before they were able to use HRVB during stress-inducing events.
The participants in the Hassett et al. (2007) study reported that the
HRVB device was easy to use, and that they benefited from the
biofeedback training and would recommend the treatment to
others. None of the other studies provided anecdotal reports or
qualitative data about the participants’ self-reported experiences
with HRVB.
Patient Characteristics
The ratio of women to men in the studies reviewed was almost
2:1 (62:36), and only 1 transgender individual was included. Soer
et al., (2014) linear regression analysis did not report any signifi-
cant relationship between a change in HRV coherence score and
gender. The remaining studies did not report a relationship be-
tween gender and measured outcomes.
Table 2
Theory of Symptom Self-Management Concepts Included in Studies
Self-Management
Concepts
Wilson (2017) Hassett et al. (2007) Soer et al. (2014) Berry et al. (2014) Hallman et al. (2011) Weeks et al. (2015)
Patient
characteristics
Age 18-78 18-60 Mean 44 Adult Mean 42 Mean 58
Gender 56 F; 15 M; 1T 12 F 71F; 99 M 1M; 13F 21 F 5 F; 6M
Mental health
status
NR NR NR NR NR NR
Sleep quality NR NR NR NR NR NR




NR NR NR NR NR




NR NR NR NR 6 Employed; 5
unemployed
PSE interventions
Observation X X X X X X
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Verbal Verbal NR NR NR NR
Self-interpretation
of HRVB skills
Light display Light display Light display Light display Light display Light display
Symptoms
Pain severity X X X X X X
Fatigue NR : NR NR NR NR
Depression NR NR : : X NR





NR NR NR NR NR X
Consistent use of
HRVB
NR NR NR NR NR X
Performance
outcomes
Functional status NR : NR NR NR NR




F ¼ female; HRV ¼ heart rate variability; HRVB ¼ heart rate variability biofeedback; M ¼ male; NR ¼ not reported; T ¼ transgender.
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Depression, anxiety, and negative moods were outcomes
measured in most of the studies (Berry et al., 2014; Hallman et al.,
2011; Hassett et al., 2007; Soer et al., 2014; Wilson, 2017). Howev-
er, none of the studies reported howmental health statusmight have
affected pain. Only Hassett et al. (2007) reported sleep quality. They
administered the Pittsburg Sleep Quality Index, a 19-item self-rated
questionnaire, and reported improved sleep quality (p ¼ .0148) that
was not sustained at the 3-month postintervention follow up.
Wilson (2017) was the only researcher to report marital status:
28 married, 2 with significant others, 23 single, 16 divorced, and 2
legally separated participants. There was no reported association
between marital status and HRV outcomes.
Employment status was only reported in two studies (Weeks
et al., 2015; Wilson, 2017). Most individuals were either employed
(n ¼ 34) or disabled (n ¼ 30); the remaining participants were
unemployed (n ¼ 12) and retired (n ¼ 7). Neither author reported
how employment status might have affected the outcomes.
Symptoms
The symptoms of fibromyalgia covered in this review are pain,
fatigue, depression, and HRV. Methods of pain measurement varied
greatly between each study and are detailed in Table 1. Most studies
reported a statistically significant reduction in pain with HRVB
(Berry et al., 2014; Hallman et al., 2011; Soer et al., 2014; Weeks
et al., 2015; Wilson, 2017). However, there was no statistically
significant difference in pain reduction between the treatment and
control groups (p ¼ .049, p ¼ .15) in the two RCTs (Hallman et al.,
2011; Soer et al., 2014). Hassett et al., (2007) reported that
although pain reductionwas not statistically significant (p¼ .0455),
it was sustained at the 3-month follow-up (p ¼ .006).
Only one study measured fatigue as an outcome. Hassett et al.
(2007) administered the Fibromyalgia Impact Questionnaire (FIQ),
a 19-item self-reported questionnaire designed to measure fatigue
among other physical impairments, and reported an improved FIQ
score (p ¼ .0686) at the end of session 10 compared to session 1,
which was sustained at the 3-month follow-up (p ¼ .0022).
Overall depression scores were decreased after HRVB (see
Table 1; Berry et al., 2014; Hallman et al., 2011; Hassett et al., 2007;
Soer et al., 2014). Soer et al. (2014) reported improved self-rated
mental health scores in the HRVB group (p ¼ .38), but they were
not statistically different from those of the control group (p ¼ .39).
HRV changes were reported in all but one of the studies. Overall,
there was a statistically significant improvement (p < .01-p ¼ .023)
in HRV coherence (see Table 1).
Symptom Self-Management
Weeks et al. (2015) reported that participants in the faded HRVB
group demonstrated improved use of unassisted biofeedback after
three weeks of practice of faded visual feedback compared to full
visual HRVB training. The researchers concluded that faded HRVB
improved biofeedback skills because the participants were able to
optimize their HRVwithout the use of HRVB at the end of the study.
Performance Outcomes
Functional status and quality of life were measured by Hassett
et al. (2007) with the FIQ. In their study, FM patients reported
improved scores (p ¼ .0686) on the FIQ after HRVB training, which
were significantly sustained (p¼ .0022) 3 months postintervention
(Hassett et al., 2007). Hallman et al. (2011) and Soer et al. (2014)
administered the SF-36, a 36-item questionnaire designed to
assess health-related quality of life. They reported improved
physical functioning, improved vitality, and improved social func-
tioning after HRVB training.
HRVB Technology
The HRVB technology across all studies used visual biofeedback
projected onto a screen. Freeze Frame, manufactured by Heart-
Math, was used in two studies (Soer et al., 2014;Weeks et al., 2015).
The J&JJ-330 unit, a visual handheld device, was used by Hassett
et al. (2007) and Hallman et al. (2011). Wilson (2017) used Relax-
ing Rhythms from Unyte Health, Inc. None of the authors provided
reliability or validity data to support the results. None of the au-
thors reported any contraindications to using HRVB. However,
some did report participant use of beta blockers and a diagnosis of
coronary artery disease as an exclusion criterion (Berry et al., 2014;
Hallman et al., 2011; Soer et al., 2014).
Discussion
The purpose of this review was to examine the relationship
between HRVB and FM-related pain through the lens of the TSSM
and to identify the HRVB technology used to treat FM pain. How-
ever, as discussed earlier, we included studies of chronic muscu-
loskeletal pain. When pain management was evaluated against the
central tenet of TSSM, that functional and cognitive patient out-
comes are improved by enhancing self-directed and self-
management behaviors, significant gaps were identified.
PSE-Enhancing Interventions
Interventions that include self-management skills support self-
efficacy and improve self-care (Fu et al., 2004). Lehrer et al. (2013)
developed a protocol and manual for HRVB training and recom-
mended five in-office sessions for participant instruction and home
practice 20 minutes twice daily for 3 months, followed by 20-
minute practice sessions every 2-3 days to maintain benefits. The
frequency and duration of HRVB practice reported in this review
were inconsistent, making it difficult to determine how much
practice is ideal for skill mastery and optimal outcomes. The re-
searchers and clinicians taught the participants how to use HRVB;
however, we do not know how this affected the outcomes or if the
participants truly understood the instructions.
Patient Characteristics
Physiological, psychological, and contextual patient character-
istics significantly influence performance outcomes such as quality
of life and functional status (Hoffman, 2013; Iversen, 2003).
Although FM patients are more likely to suffer from depression and
sleep disturbances than those with other chronic pain disorders
(Cohen, 2017), the studies reviewed did not include these variables.
The studies reviewed did include sex as a variable but did not report
how this may have affected the outcomes. The female-to-male ratio
of FM sufferers in the general population is 2:1; however, the
female-to-male ratio was almost 1:1 in the studies reviewed. This
review thus may not be an accurate representation of FM patient
outcomes. Psychosocial issues like marital status and employment
status may contribute to FM symptoms (Cohen, 2017) and are
associated with increased divorce rates (Wolfe et al., 1995); never-
theless, these factors were underrepresented and their significance
was not discussed in the studies reviewed.
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Symptoms
Overall, there was a statistically significant reduction in pain
after HRVB compared to control groups in all but one study, sup-
porting the current recommendations for patient-centered non-
pharmaceutical pain treatment (Babu, Mathew, Danda, & Prakash,
2007; Cohen, 2017; Gevirtz, 2013) and self-management
enhancing interventions (Fu et al., 2004; Hoffman, 2013). Howev-
er, sustained pain reduction was evaluated in only two of the six
studies and seen in only one 3-month follow-up study. Four of the
studies demonstrated a statistically significant increase in HRV, but
this did not translate into decreased pain, increased resilience,
improved emotional state, or improved stress resistance. None of
the studies discussed pharmacological treatment or its effects on
pain. Sleep disturbance and fatigue are known triggers for FM pain
(Clauw, 2014; Wolfe et al., 2010) and should be included as out-
comes in future studies. Overall, mood improved with HRVB.
Depression scores decreased (Hallman et al., 2011; Hassett et al.,
2007), negative mood improved (Berry et al., 2014), and self-rated
mental health scores increased, indicating improved mental
health (Soer et al., 2014).
Symptom Self-Management
HRVB is designed to provide patients with a self-directed active
behavior to self-manage pain. Once the patient has demonstrated
adequate HRVB skills in the clinic setting, he or she may receive a
prescription from the clinician for home use. The patient can then
self-determine the correct use of HRVB by following the prompts
from the device. Consistent and correct use of the HRVB training
device can allow the patient to self-manage his or her pain. Clini-
cians can verify consistent and correct use outside of the clinic
setting by reviewing the reports generated by the software of the
HRVB device. However, only one study,Weeks et al. (2015) reported
that participants who used HRVB at the prescribed frequency re-
ported decreased pain postintervention.
Performance Outcomes
Functional status and quality of life are the performance out-
comes evaluated in this review. Again, Hassett et al. (2007), the only
study involving FM patients, measured outcomes with the FIQ. The
FIQ is a reliable instrument used to measure quality of life and
functional status (Iversen, 2003). Although the researchers re-
ported improved scores, the improvement was not statistically
significant. However, Soer et al. (2014) and Hallman et al. (2011)
administered the SF-36, a questionnaire that measures quality of
life by evaluating self-report of physical function, vitality, and social
function. Both studies reported an increase in these measures post-
HRVB intervention. These instruments would be appropriate for
future studies.
HRVB Technology
This review demonstrated that there are several biofeedback
devices available on the market for HRV modulation. The authors
did not provide reliability or validity data about the HRVB devices,
making it challenging to support their use in future studies. The
monetary cost of the devices was not given, and there was no
discussion of software or device problems reported during the
study. Although there was no discussion of any contraindication to
HRVB, it can be assumed that participants with coronary artery
disease could face risks from HRVB.
Strengths and Limitations
There were several limitations in this review. First, the pilot
studies were small and not guided by power analyses; second, the
larger studies were retrospective non-randomized controlled trials.
None of the studies compared HRVB to sham or other biofeedback.
Second, only one of the studies was on FM exclusively, so other
chronic pain studieswere included, although it has been established
in the literature that the pain caused by FM is different from that of
other disorders (Clauw, 2014;Wolfe et al., 2010). None of the studies
evaluated stress resistance, amarkerof optimalHRVanda functional
ANS (Cho et al., 2011; Kang et al., 2012; Meeus et al., 2013; Mostoufi
et al., 2012). Additionally, no qualitative or mixed-method studies
were identified. Such studies could enhance our knowledge of the
effectsHRVBmayhaveon chronic pain, quality of life, and functional
status. Lastly, we did not search the literature for different biofeed-
back devices; this may have yielded additional studies.
Conclusion
FM is a debilitating, painful condition affecting 2% of the pop-
ulation (Wolfe et al., 1995) with relatively few effective treatments
available (Macfarlane et al., 2017). Current recommendations for
FM treatment by the European League Against Rheumatism and the
Canadian Pain Society include non-pharmacological therapies such
as biofeedback (Clauw, 2014; Macfarlane et al., 2017). Although
HRVB is a promising treatment modality for chronic pain, only one
studywas found that evaluated the relationship between HRVB and
FM pain (Hassett et al., 2007). Future research is needed to thor-
oughly evaluate the relationship between FM and HRVB.
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BACKGROUND: Fibromyalgia (FM) is characterized by diffuse pain, fatigue, sleep 
disturbance, and depression leading to decreased functional status and poor quality of life 
(QOL). Research suggests that autonomic dysfunction and diminished heart rate variability 
(HRV) may explain some symptoms of FM. The purpose of this study was to determine 
feasibility and acceptability of heart rate variability biofeedback (HRVB) to treat FM. 
METHODS: We enrolled 10 Veterans for 8 weeks of HRVB training to determine the feasibility 
to adhere to a recommended HRVB protocol and to examine acceptability and satisfaction with 
the intervention. They were taught how to use the emWave2 biofeedback device and asked to 
practice with the device at home twice daily for 20 minutes. We collected data from the device to 
evaluate their ability to adhere to the treatment protocol. Data collected at sessions 2-8 provided 
a signal of efficacy from HRVB for pain control, heart rate coherence, functional status, and 
QOL. 
FINDINGS: Most Veterans believed HRVB is a viable treatment for FM that will reduce pain 
by 50-80%. Data suggest a twice-daily HRVB practice protocol is not feasible. However, once 
daily 20-minute HRVB home sessions were feasible and acceptable to study participants. HRVB 
contributed to an improvement in functional status and QOL within our sample.  
CONCLUSION: It appears that although a twice-a-day HRVB practice protocol is not feasible, 
when Veterans did practice once daily, 20-minute HRVB sessions were acceptable. HRVB may 









Fibromyalgia (FM) is a complex, painful condition with predominant symptoms of pain, 
fatigue, depression, and sleep deprivation that lead to a significant decrease in functional status 
and diminished quality of life (1). Individuals with FM often report symptoms that are variable 
and unpredictable, leading to frustration and often feeling as if family members, friends, and 
health care providers do not believe them (2, 3).  
The fatigue, memory problems, cognitive impairment, and functional limitations 
associated with FM (4, 5) contribute to 1-2% loss of national U.S. productivity (6, 7), and $12-14 
billion per year in national health care costs (6). The Department of Veterans Health 
Administration (VA) and Department of Defense (DoD) recognize FM as an illness potentially 
linked to injuries and exposures sustained during the Persian Gulf War (8).  
The DoD and VA have linked FM to the physical and emotional trauma sustained by 
service members who deployed during wars in the Persian Gulf and in Afghanistan, as well as to 
the various natural and artificial environmental exposures in that region (9). Individuals 
diagnosed with FM have a higher prevalence of traumatic events such as those experienced in 
combat and in physical and sexual abuse (10, 11). Repetitive muscular injuries are attributed to 
service members carrying over 80 pounds of equipment daily for 6-12 months during multiple 
deployments, which has resulted in more than 50% of service members/Veterans returning from 
these conflicts reporting chronic pain not related to direct injuries such as shrapnel, gunshots, or 
blasts (9, 12, 13). The FM cost to the military health care system in 2006 was $105.6 million, 
with an average individual cost of $12,472; this is five times higher than the utilization costs on 
non-fibromyalgia diagnosed military beneficiaries (14). The incidence of FM diagnosis and FM-
related disability in the VA system is rising at an alarming rate (14). 
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The American College of Rheumatology has set the FM diagnostic criteria (5). FM 
diagnosis is satisfied with one of the following 3 conditions: 1) the Widespread Pain Index 
(WPI) ≥ 7, the Symptom Severity Score (SS) ≥ 5, or the WPI = 36 and the SS ≥ 9; 2); symptoms 
are present and at a similar level for at least 3 months; or 3) the patient lacked a disorder that 
would otherwise explain the pain (5). 
Pathophysiology of FM 
Research utilizing functional magnetic resonance imaging (fMRI) demonstrates that 
among individuals with FM, there is a disruption of the pain network connectivity (15). 
Strengthened connectivity of the brain regions involved in processing and reducing connectivity 
of the regions involved in pain inhibitory modulation may explain this widespread chronic pain 
(15). The default mode network (DMN), a constellation of brain regions engaged in self-
referential thinking, is disrupted in FM during tasks like visual attention and cognitive attention, 
which may explain symptoms of memory problems and cognitive impairment (16, 17). An 
abnormally increased level of connectivity between the DMN and the insular cortex may also 
explain higher reported pain levels (17). Additionally, a dysfunction of the cardiac autonomic 
nervous system (ANS), characterized by higher sympathetic and lower parasympathetic cardiac 
autonomic modulation, is associated with diminished heart rate variability (HRV) and is related 
to the impact of FM on quality of life (18, 19).  
Heart Rate Variability  
Heart rate variability (HRV) is the time measurement of the oscillations of the R-to-R 
intervals (20-22) and reflects heart-brain interaction and the ANS (21, 23). HRV reflects the 
activity of the sympathetic and parasympathetic nervous systems providing information on how 
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the systems interact and function as a whole (24). Thus, analyzing HRV provides quantitative 
information about the state of the ANS (19). 
HRV is measured on spectra analysis via high frequency (HF) (0.15-0.40 Hz) and low 
frequency (LF) (0.04-0.15) bands. The LF is influenced by sympathetic activities like significant 
psychological and physiological activities, and parasympathetic conditions of slow breathing (6 
breaths per minute) (25). Optimal HRV, cardiac coherence, is an ordered, harmonic cardiac 
pattern reflecting positive emotions and a general sense of well-being (23). Low HRV, cardiac 
incoherence, reflects decreased resistance to stress, anxiety, and decreased emotional adaptability 
(19, 21, 23, 26), factors known to exacerbate chronic pain. Self-regulation techniques that 
increase HRV coherence can reduce pain, improve physical activity, and improve cognitive 
function (23).  
Treatment Recommendations 
 The ANS dysfunction and diminished HRV associated with FM are generally not 
demonstrated in chronic musculoskeletal pain; thus, comparing treatment between these pain 
syndromes is challenging (5, 19). The most commonly used guidelines for FM treatment are 
from the European League Against Rheumatism (EULAR) 2008, revised in 2016, American Pain 
Society (APS) 2005, German Association of the Scientific Medical Societies (AWMF) 2013, 
Israeli Pain Society (IPS) and Canadian Pain Society (CPS) (1, 27). There is a consensus among 
the EULAR, APS, AWMF, IPS, and CPS guidelines that effective treatment must include a 
multidisciplinary approach that prioritizes nonpharmacological treatments, offers judicious 
pharmacological treatments (1, 27), and reflects the biopsychosocial model (1) which integrates 
biological, psychological and social factors into the treatment plan (28). The most recent 
VA/DoD Clinical Practice Guidelines for the treatment of chronic pain, which includes pain 
49 
 
related to fibromyalgia, are to utilize cognitive behavioral therapy, biofeedback, exercise, 
multidisciplinary psychosocial rehabilitation (4, 29), physical therapy, occupational therapy, 
acupuncture, spinal manipulation, and/or complementary and alternative medicine (1, 12). 
Unlike chronic musculoskeletal pain, FM treatment must improve autonomic function, optimize 
HRV, and improve pain network connectivity through the DMN (17, 30).  
Heart Rate Variability Biofeedback 
 Heart rate variability biofeedback (HRVB) enables self-regulation by using technology to 
guide deep breathing at an average rate of 6 breaths per minute. This deep breathing is an 
autonomic maneuver that may intensify the interaction between autonomic and nociceptive 
pathways (18). HRVB induces HRV coherence (HRC) and ANS regulation through the 
activation of baroreceptors in the vagus nerve (18, 23, 31-34). Repeated sessions of HRVB can 
sustain improved HRC and, with sufficient practice, can be used by individuals before, during, or 
after times of increased stress or adversity, thus optimizing stress resistance and emotional 
adaptability to decrease pain and increase overall well-being (23, 31, 32). 
The purpose of this study was to determine the feasibility and adherence to a 
recommended HRVB protocol using a handheld training device (emWave2) that objectively 
monitors HRV and displays the physiological level of HRC among Veterans with FM. 
Additionally, we examined the feasibility of recruitment and retention of Veterans diagnosed 
with FM, along with acceptability and satisfaction with HRVB. Finally, we collected data related 
to HRC, qualities of pain, and FM symptoms, including overall function and QOL, as an initial 






The theory of symptom self-management (TSSM) was used to guide this study. TSSM is 
effective in assisting individuals in reducing, relieving, or decrease the frequency and duration of 
pain, through the use of self-management enhancing interventions like biofeedback (35, 36). The 
central tenet of TSSM is that when self-directed, self-managed, perceived self-efficacy-
enhancing interventions (PSI) such as HRVB are optimized, cognitive performance outcomes, 
such as quality of life and functional status, are improved (36, 37). Additionally, cognitive 
behavioral strategies, like HRVB, improve self-efficacy and shift the individual’s perception of 
helplessness to a sense of ability to self-improve (38). 
Methods  
Investigator HRVB Training 
The Principal Investigator (PI) completed the HeartMath® Interventions Certification 
Program for Health Professionals (39), designed for physicians, advanced practice nurses, and 
other health professionals who want to add HRVB techniques to their practice prior to study 
implementation. The program consists of six 90-minute live and recorded webinars, home study, 
and video presentations.  
Participants/Recruitment 
This feasibility study was not designed to test a hypothesis, and there was no plan to 
report inferential statistics. We based the sample size on the pragmatics of recruiting from the 
VA, patient flow, and budget constraints around the purchase of the emWave2 HRVB devices 
(40). Additionally, there are no concrete recommendations for sample size in a feasibility study; 
however, we may achieve the aims of the study with a sample of 10 participants (41) (Table 1). 
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This study was approved by the Medical University of South Carolina Institutional 
Review Board (IRB) and the Ralph H. Johnson VA Medical Center Research and Development 
Board. We placed IRB-approved recruitment flyers in the lobbies and exam rooms of primary 
care and mental health clinics of a southeastern United States VA health center. We also gave 
flyers to the primary care providers, mental health providers, and nurses in these clinics. 
Additionally, we attended the monthly meeting for clinic staff and provided information and time 
for questions and answers about the planned study. The health care providers and medical staff 
were not involved in the study and did not receive any finders’ fees. 
Inclusion criteria included male and female Veterans ages 18 and older with a 
documented diagnosis of fibromyalgia. Veterans of all races and ethnicities were eligible to 
participate. Exclusion criteria were any major cardiovascular disease, current use of medications 
that regulate heart rate, major pulmonary disease, a major psychosis diagnosis, self-reported 
pregnancy, or prior experience with HRVB. Study participants received a $5 gift card during 
each visit. 
Design  
We used a multi-method design to inform the following questions: 1) Is it feasible to 
recruit and retain Veterans from a VA on the southeast coast of the United States in a study 
implementing HRVB to treat FM-related chronic pain? 2) Is it feasible for Veterans to adhere to 
the recommended HRVB protocol? and, 3) Will Veterans find this intervention acceptable?  
Procedures 
 Consistent with prior studies and recommendations from the developers of the emWave2 
(32, 42-44), we conducted an initial feasibility trial of HRVB practice 8 once-weekly one-hour 
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individual sessions with each participant. After participants provided informed written consent, 
we proceeded with the initial study visit.  
Initial Visit  
During the initial visit, the participants provided demographic data, completed the 
Credibility/Expectancy Questionnaire (CEQ), Revised Fibromyalgia Impact Questionnaire 
(FIQR), and Short form McGill Pain Questionnaire (SFMQ). Each participant received an 
emWave2 handheld device, USB connector, ear sensor, quick start guide, and practice plan to use 
in the clinic and to take home for practice. We demonstrated the proper use and care of the 
device, including how to clip the enclosed photoplethysmograph (PPG) sensor on the 
participant’s ear. Participants were shown features on the device, such as a blinking blue light 
that indicated the reading of the participant’s pulse. The study team assisted with the 
configuration of initial settings to default level 1 (low) using the Quick Start Guide included in 
the box. The participant was provided time to practice HRVB during the initial visit, which 
included being able to see a rising and falling light in the Heart Action Strip with each breath, 
indicating heart rhythm and HRC. The participant was instructed to take slow rhythmic breaths. 
The goal was to increase HRC and change the coherence level indicator from red (low 
coherence/baseline) to blue (medium coherence/ improving), to green (high coherence/optimal), 
and to remain in the green zone as long as possible during the 20-minute practice session. 
Additionally, based on the protocols used by Lehrer et al. (45), participants were instructed to 
practice with the device at home for 20 minutes twice daily. We provided the participants with a 






 During visits 2-8, participants completed the SFMQ and the FIQR. We downloaded and 
stored the physiological data from the participant’s emWave2 and discussed the results with each 
participant. We discussed any problems with the device or barriers to practicing as 
recommended. We discussed strategies to overcome practice barriers and to troubleshoot any 
technical difficulties. Participants practiced on their emWave2 devices for 20 minutes during 
each visit and received additional breathing technique coaching as needed. 
Variables and Their Measures 
 We collected standard demographic data during the initial visit: age, gender, race, 
ethnicity, education level, employment status, mental health history, and marital status. We also 
asked about the frequency of aerobic physical activity, strength training, and stretching per week. 
See Table 1 for demographic data. 
 We measured treatment outcomes expectancy and credibility with the CEQ at the initial 
visit to assess HRVB as a perceived method of FM symptom management (46). Four CEQ 
questions ask if individuals expect treatment to improve their symptoms (expectancy), and two 
questions ask about treatment believability and logic (credibility) (46, 47). The CEQ has 2 rating 
scales, 1 to 9 (not at all to very much) and 0% to 100 % (not at all to very much). Percentage 
ratings are transformed linearly to a scale of 1 to 9 (minimum to maximum), allowing for a sum 
score ranging from 3 to 27 (minimal to maximum credibility and expectancy) (47). In previous 
studies, treatment expectancy has correlated higher with treatment outcomes than treatment 
credibility (46, 47). There is a high internal consistency of the expectancy factor (Cronbach’s α 
between 0.79 and 0.90), the credibility factor (Cronbach’s α 0.81 and 0.86), and a standardized α 
of 0.84 to 0.85 for the whole scale (both factors) (46). 
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We assessed the sensory and affective quality of pain with the Short-form McGill Pain 
Questionnaire (SFMQ). The SFMQ consists of 11 sensory and 4 affective descriptors of pain 
(48). Each word is scored on a 4-point ordinal scale and totaled for a Pain Rating Index of 0 to 
45 (no pain to severe pain) (48). When the SFMQ was used with FM patients, Cronbach’s alpha 
was estimated at α = 0.73-0.89, and test-retest reliability ranged from 0.45-0.73 for one- and 
three-month intervals (49). The SFMQ moderately correlated with the Western and Ontario and 
McMaster Universities Osteoarthritis Index and the Short Form 36 Health Survey bodily pain 
scales (r=0.36 and -0.36 respectively; p <0.01) in 200 patients with hip and knee osteoarthritis 
(50). 
Participants also were asked to complete the FIQR at the start of each visit. The FIQR 
consists of 21 questions that are divided into 3 domains: function, global impact, and FM-related 
symptoms in the past 7 days (51). Questions are rated on a 0 to 10 numeric scale, with a better 
quality of life being a lower total FIQR score (51). The Cronbach’s alpha coefficient measures in 
the 3 domains were 0.90 for function, 0.81 for overall impact, and 0.89 for the severity of 
symptoms (52). The FIQR was closely correlated with the Fibromyalgia Impact Questionnaire 
(r=0.69 to 0.88, p< 0.01) (51). The 3 domains in the FIQR also closely correlated with the 36-
Item Short Form Health Survey: function (r= -0.26 - -0.80), global impact (r= -0.30 - -0.64), and 
symptoms of FM (r= -0.43 - -0.66) (51). 
 Computer software calculated HRC as the ratio between low frequency (LF) HRV 
divided by the sum of the high frequency (HF) and LF (53). The resulting average weighted 
score ranged from 0 to 200 (low coherence to high coherence) (53). We collected and recorded 
the HRC scores, session duration, session frequency, and heart rate from the emWave2 at each 
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study visit. Data, including practice frequency and time spent using the emWave2 device, were 
downloaded into the HeartMath software and reviewed with the participant at each study visit.  
Results 
Participant Characteristics  
We enrolled 7 women between the ages of 33 and 68 years (mean=52) and 3 men 
between the age 33 and 54 years (mean =47). Participants were white (n=5), African American 
(n=4) or Hispanic (n=1). All had at least some higher education (Table1). Only 3 participants 
were employed. All participants had a mental health diagnosis, including depression (n=6), 
anxiety (n=2), and/or post-traumatic stress disorder (PTSD) (n=4). Most were married. Fifty to 
60% of the Veterans self-reported that they never exercise (Table 2). 
Table 1. Participant demographics and baseline history 
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GED: General educational diploma 
College: Bachelor’s degree 
Graduate: Post-Bachelor’s degree 
PTSD: post-traumatic stress disorder 
 
Table 2. Self-reported weekly exercise frequency 
 Never 
n / % 
1-2 x/week 
n / % 
3-4 x/week 
n / % 
5-6 x/week 
n / % 
7 x/week 
n / % 
Aerobic 5 / 50 1 / 10 3 / 30 1 / 10 0 
Strength 6 /60 3 / 30 0 1 / 10 0 
Stretching 5 /50 1 / 10 1 / 10 3 / 30 0 
 
HRVB Practice 
Frequency. Participants were instructed to practice HRVB for 20 minutes during their 
weekly study visits and 20 minutes at home twice daily. All practice sessions were recorded by 
the emWave2 software. The mean daily practice frequency rate was 0.80, suggesting there were 
days when the participants did not practice at all. One participant practiced twice daily during the 
first week of the study but not for the prescribed 20 minutes; after that, he only practiced 1-1.3 
times per day but for longer periods (25.3 – 39.3 minutes). One participant only practiced during 
the first week (mean frequency 0.1), did not practice during week 2, then stopped attending, and 
did not return the emWave2, which would have allowed us to collect any additional data. Women 
practiced 21.46% more frequently than men (Table 3). All participants had a mental health 
diagnosis (Table 1); those with depression practiced 24.4% more frequently than those with 
anxiety and 27.16% more frequently than those with PTSD. Not employed Veterans practiced 





















Time (minutes). Participants were instructed to practice 20 minutes each session. The 
mean practice duration in minutes was 19.36 and ranged from 0 to 58.1 (Table 3), suggesting 
that when participants practiced, they did so for the prescribed time. Women practiced 17.57% 
longer than men (Table 3). Veterans with a PTSD diagnosis practiced 22.21% longer than those 
with a diagnosis of anxiety, and 11.85% longer than those with a diagnosis of depression (Table 
3). Those who were not employed practiced only 0.41% longer than those who were employed 
(Table 3). 













 10 0.80 (0.51) 19.36 (11.36) 0 - 58.1 
Female 7 0.86 (0.49) 21.12 (10.35) 0 - 58.1 
Male 3 0.61 (0.60) 14.01 (16.63) 0 - 39.3 
Depression 6 0.92 (0.52) 19.68 (9.6) 0 - 39.3 
Anxiety 2 0.72 (0.40) 17.73 (5.71) 0 – 22.8 
PTSD 5 0.70 (0.53) 22.16 (13.83) 0 – 58.1 
Employed 3 0.59 (0.36) 19.31 (9.07) 0 – 37.2 
Not 
employed 
7 0.89 (0.57) 19.39 (12.4) 0 – 58.1 
 
CEQ  
 We assessed CEQ at the baseline visit. Nine of the participants believed HRVB is a 
logical treatment and anticipated it would successfully reduce their pain (n=7). Most expected 
50% or greater improvement in their pain (n=8). When asked about how the participants really 
feel, half of the participants (n=5) felt that HRVB would reduce their pain, and most (n=7) felt 
HRVB would reduce their pain by 50-80%. Prior to trialing the intervention, nine of the 






 FIQR scores were measured at baseline and during weekly study visits thereafter; scores 
for each of the three domains and the total FIQR score range from low to high (Table 4). A lower 
score represents a better quality of life (51). Functional domain and global impact domain scores 
improved post-intervention, suggesting a slight improvement in functional status after HRVB 
(Table 4). The mean scores from symptoms of FM were essentially unchanged (63.9 - 64.9), 
indicating HRVB did not affect symptoms of FM. The weekly mean total FIQR scores post-
intervention (128.5) were lower than at baseline (146.6), indicating HRVB improved overall 
quality of life. 
SFMQ 
 Pain scores were measured using the SFMQ at baseline and at each weekly visit. Pain 
scores did not vary greatly pre- and post-intervention (Table 4). The mean total pain rating index 
score was 25.4 at baseline and 25.9 at weekly visits, suggesting there was no improvement or 
worsening of pain pre- and post-intervention. 
HRC 
HRC was measured each time the participant practiced HRVB (Table 4). The mean HRC 
recorded at baseline was 1.0, with a range of 0.3 to 1.72. Post-intervention the mean score was 
unchanged (1.05); however, we saw a broader range (0.46 to 2.38), suggesting a 29.94% increase 
in HRC scores for post-intervention. The highest scores (1.83-2.52) were reached by the two 
participants who had the highest rates of HRVB practice frequency (1.1 and 1.9). When we 
examined the frequency (n=57) of mean scores, we noted 7 out of 57 practice sessions resulted in 
a greater HRC maximum base score of 1.72, indicating most practice sessions (n=50) did not result 
in improved HRC week to week (Figure 1).  
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Table 4. Outcomes measurements 
 Baseline Post-Intervention 
































































HRC  1.0 0.3-1.72 0.51 1.05 0.46-2.38 0.59 
 
 
Figure 1. Scatter plot of HRC total means 
 
Discussion 
 A purpose of this study was to evaluate the feasibility of Veterans adhering to a 
recommended HRVB protocol of twice daily twenty-minute sessions (45) using the emWave2 
training device that objectively measures HRV and displays the physiological level of HRC. The 
data suggest that twice daily HRVB practice sessions were not feasible for most study 
participants. Only one in 10 Veterans, a male, practiced twice daily and then only for one week. 
However, overall women practiced more frequently and for longer periods than the men. Three 
of the ten participants were employed, which may have impacted their ability to practice twice 
daily. Three participants reported frustration with operating the device. Two of them had 
difficulty getting a pulse reading from the PPG sensor clipped on their ear, which caused the 
device to shut off automatically after a few minutes. One was not able to operate it during the 
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last two weeks of the study, and he did not call for assistance or come for his weekly clinic visits. 
One participant reported chest wall discomfort if she practiced for more than 10 minutes, so she 
avoided trying to practice twice daily. Veterans diagnosed with depression practiced more 
frequently than those with PTSD and anxiety. However, Veterans diagnosed with PTSD 
practiced for longer periods that those diagnosed with anxiety or depression. This group of 
Veterans demonstrated that when they did practice HRVB, they were able to complete a single 
20-minute session and some participants tried to make up for the missed sessions with longer 
sessions. 
The poor adherence to the practice protocol was surprising because most of the 
participants reported on the CEQ they believed the treatment was logical and would reduce their 
pain by 50-80%. In previous studies, treatment expectancy correlates with treatment outcomes 
(46, 47). Additionally, we expected greater adherence given weekly in person sessions with the 
PI. We reviewed adherence rates and discussed any barriers to protocol adherence, such as 
difficulties with the device and scheduling practice times, at each in person session. The 
participants’ poor adherence is more consistent with previous reports that FM patients are 
skeptical of treatments (2). We have found no prior HRVB protocol feasibility studies with 
which to compare our results. One prior study of HRVB for FM-related chronic pain prescribed 
twice daily practice (32); however, the researchers did not report treatment protocol adherence 
rates. Other prior HRVB studies for chronic pain did not follow the treatment protocol 
recommendations set by Lehrer et al. (45); the studies only provided HRVB training during 
clinic visits (31, 43, 54, 55). 
The emWave2 software calculates the HRC scores. A lower score indicates a less 
coherent HRV, reflecting a dysfunctional ANS, increased pain perception, decreased physical 
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function, and poor quality of life (QOL) (19, 21, 56). In our study, the mean HRC scores did not 
change substantially from week to week, suggesting there was no improvement in HRV post-
intervention. This finding is inconsistent with earlier studies, where HRC scores increased with 
HRVB (31, 32, 43, 54). Hassett et al. (32) conducted a pilot study of the efficacy of HRVB in 
patients with FM and demonstrated a statistically significant (p=0.002) improvement in HRC 
after 10 weekly sessions of HRVB training. Soer et al. (43) and Berry et al. (31) conducted pilot 
studies of the efficacy of HRVB on chronic pain and also demonstrated a statistically significant 
(p < 0.01 and p = 0.01) improvement in HRC after 6 and 4 (respectively) sessions of HRVB 
training. 
The goal of HRVB is to improve QOL and functional status by decreasing FM-related 
symptoms. Data from the SFMQ and the FIQR suggest there was no improvement in pain 
symptoms following HRVB. However, despite the persistent pain scores, data from the FIQR 
suggests an improvement in the functional status, and an overall improvement in QOL post-
intervention. Similar findings were reported in the HRVB study for FM patients by Hassett et al. 
(32) where they reported a statistically significant (p = 0.0002) improvement in FIQR scores 3 
months post intervention, indicating an improvement in QOL. Improved QOL indicators support 
treatment that addresses the dysfunctional ANS present in FM (18, 19).  
Conclusions 
 Major limitations of this study were its small size and the lack of a control group. It was 
not possible to make inferences about changes in pain, HRV, QOL, or functional status post-
intervention. Future studies should enroll an adequate number of participants to detect true 
changes in outcomes pre-and post-intervention. The participants all self-selected to trial HRVB 
and reported a high treatment outcome expectancy of 50-80% improvement in pain. Comparing 
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HRVB to sham biofeedback may minimize this self-selection bias. Future studies should also 
investigate the protocol adherence correlations between mental health diagnoses. 
In summary, it appears a protocol of twice-a-day HRVB practice is not a feasible 
treatment option for these Veterans with FM. Yet, the Veterans in this study demonstrated that 
once-daily 20-minute practice sessions are acceptable. Findings suggest HRVB was effective in 
improving functional status and QOL among our study participants with FM-related symptoms. 
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Abstract 
Introduction: The repetitive musculoskeletal stress of wearing heavy gear and exposure to 
natural and artificial environmental hazards in the Persian Gulf region has increased the 
prevalence of fibromyalgia (FM) among service members. Heart rate variability biofeedback 
(HRVB) is a self-management strategy that guides individuals to breathe at a designated 
resonance frequency of the cardiovascular system. Resonant breathing may reduce FM-related 
symptoms as well as improve physical functioning and quality of life. Although prior research 
recommends HRVB for chronic pain, we found no studies testing the feasibility for individuals 
with FM regarding protocol adherence or acceptability of the treatment. 
Methods: We enrolled 10 Veterans in a HRVB study using a recommended protocol to treat 
FM. Veterans were given a HRVB device, emWave2, and instructed to practice at home twice 
daily for 20 minutes per session. Following a 7-week intervention period, we conducted an end 
of study focus group. We used content analysis to develop themes to determine the feasibility of 
engaging in HRVB and adhering to the intervention protocol, as well as insights of Veterans 
about the intervention. 
Findings: Three common themes emerged: intervention implementation, protocol adherence, 
and self-awareness.  
Conclusions: Results of this study suggest difficulties operating the emWave2 and scheduling 





awareness of the benefits of HRVB to treat FM-related symptoms. Future studies require a larger 
sample size to provide a deeper insight. 
Key Words: Fibromyalgia, Veterans, heart rate variability biofeedback, heart rate variability, 
focus group  
Introduction  
Fibromyalgia (FM) is a complex condition characterized by chronic generalized myalgia, 
anxiety, depression, sleep disturbance, and fatigue (1). Individual reports of symptoms are 
variable with time of day, mood, external stressors, ambient temperature, or the amount of sleep, 
leading to dissatisfaction of overall health status (2). Individuals with FM are often frustrated by 
the lack of clarity of diagnosis (3) and very little information about treatment options from health 
care providers (4).  
The Veterans Health Administration (VA) and Department of Defense (DoD) 
acknowledge that the repetitive musculoskeletal stress of wearing heavy gear every day during 
multiple 6 -12-month deployments during the Gulf War and Afghanistan War increased the 
prevalence of FM among service members (5). Additionally, the DoD recognizes that exposure 
to natural and artificial environmental hazards in the Persian Gulf region may also contribute to 
the symptoms of FM (5). The American College of Rheumatology have set the diagnostic 
criteria of FM (6). The diagnosis is based upon the individual’s self-evaluation of pain location 
and symptom severity over the past weeks, the symptoms must occur at a similar level for at 
least 3 months or lack a disorder that would otherwise explain the pain (6). Because the VA and 
DoD have recognized FM as a service-connected condition (5), Veterans have been seeking FM-







In individuals with FM, functional magnetic resonance imaging has demonstrated 
disruptions in the regions of the brain that modulate pain inhibition and engage in self-referential 
thinking, possibly explaining the symptoms of widespread pain, memory problems, and 
cognitive impairment (8, 9). Additionally, the cardiac autonomic nervous system is disrupted, 
resulting in an incoherent heart rate variability (HRV) and impacting quality of life (10, 11). 
Heart Rate Variability 
HRV provides information on the sympathetic and parasympathetic interactions between 
cardiac autonomic nervous system (ANS) and ANS, as well as how they function as a whole 
(12). HRV is non-invasively analyzed from a plethysmographic (PPG) optical sensor placed at 
the fingertip or earlobe (12). HRV coherence, an ordered and harmonic sine-waveform (13), 
reflects a healthy functioning ANS associated with minimal pain (14), stress resistance, 
emotional adaptability (15), and self-regulation (13). HRV incoherence, an erratic or chaotic 
waveform pattern (13), reflects a dysfunctional ANS associated with the chronic pain, decreased 
physical functioning, and poor quality of life seen with FM (10, 14, 16). 
Treatment  
FM treatment is complex, and treatment recommendations vary. However, there is a 
consensus in the major guidelines that effective treatment should prioritize non-pharmacological 
options that reflect the biopsychosocial model (1, 17). The most recent 2014 VA/DoD Clinical 
Practice Guidelines (18) recommend a step treatment for chronic pain that prioritizes multi-
disciplinary non-pharmacological modalities, which includes strategies like cognitive behavior 
therapy, exercise, psychosocial rehabilitation, physical and occupational therapy, acupuncture, 





Heart Rate Variability Biofeedback 
Heart rate variability biofeedback (HRVB) is a self-management strategy using visual 
biofeedback to guide the individual to breathe at a designated resonance frequency of the 
cardiovascular system (4-6 breaths per minute) (20). This breathing frequency causes the heart 
rate to increase with inhalation and decrease with exhalation, inducing heart rate variability 
coherence (HRC), as well as ANS regulation (11, 13, 21-24), which may intensify the interaction 
between autonomic and nociceptive pathways (11). By improving HRC and ANS regulation, 
HRVB can effectively assist individuals in reducing or preventing FM-related symptoms such as 
chronic pain, fatigue, anxiety, and memory problems (25, 26). HRVB also has the potential to 
improve emotion regulation, stress resistance, physical functioning (23, 24, 27), and QOL (13, 
21, 24) in those with FM.  
Optimal resonance breathing differs for each person, so it is difficult for individuals to 
achieve and sustain an optimal breathing rate to reach HRC by simply breathing slower than 
usual (20, 28). HRVB training must occur gradually to adjust to a such a slow rate (28). 
Biofeedback devices, such as the emWave2 (29), use a light display to guide the individual to 
breathe at his or her optimal resonant frequency, which will adapt with practice as respiratory 
and baroreflex function improve (28). Lehrer et al. (20) recommend 5 clinic visits for HRVB 
training with an HRVB-trained health care professional, along with twice-daily 20-minute at-
home HRVB practice sessions (20, 28). The developers of emWave2 recommend 4-6 training 
sessions with a trained health care provider (41), and previous studies assessed the efficacy of 
HRVB with 4 to 10 training sessions with a health care provider’s guidance (33, 35, 39). 





recommended HRVB protocol or the acceptability of the intervention to treat symptoms 
associated with FM.  
Theoretical Framework 
The Principal Investigator (PI) used the theory of symptom self-management (TSSM) to 
guide this study. The central tenant of TSSM is that when patients optimize self-directed and 
self-managed interventions they experience better cognitive performance outcomes for quality of 
life and functional status (26, 30). Additionally, perceived self-efficacy-enhancing interventions 
(PSI) like biofeedback can reduce, relieve, or decrease the frequency and duration of pain (25, 
26). Lastly, improving patient self-efficacy with cognitive behavioral strategies like HRVB can 




Aim one of this multi-method study was to explore the feasibility and acceptability of 
HRVB as a treatment for Veterans with FM-related chronic pain. Before participant recruitment, 
the Institutional Review Board (IRB) at the Medical University of South Carolina and the 
Research and Development Review Board (R&D) at the Ralph H. Johnson Veterans Health 
Administration (RJVA) in Charleston, South Carolina, approved the study protocol.  
Recruitment & Sample 
We aimed to recruit 10 participants for this study based upon recommendations for 






The PI placed IRB and RJVA R&D-approved recruitment flyers in the lobbies and exam 
rooms of the primary care and mental health clinics of the RJVA Medical Center. Additionally, 
the PI gave flyers to the primary care providers, mental health providers, and nurses in the clinics 
and provided them with information about the planned study. The health care staff was not 
involved in the study and did not receive a finders’ fees for referrals. 
 Inclusion criteria were as follows: Veterans of all races, ethnicities, and genders; aged 18 
or older; with a documented diagnosis of fibromyalgia. Exclusion criteria were as follows: a 
history of a major cardiovascular or pulmonary disease, current use of heart rate regulating 
medications; major psychosis; self-reported pregnancy; or prior HRVB experience.  
To promote participation and retention, participants received a $5 gift card following 
completion of each visit. The PI also reminded participants of the date and time of their next visit 
and called them the day before the visit to remind them again. 
Intervention  
After eligible participants consented, they were enrolled and started the study. Based 
upon practice protocols recommended by Lehrer et al. (20) and earlier studies of HRVB to treat 
chronic pain (23, 24, 27, 34, 35), the PI conducted 8 once-weekly one-hour individual sessions 
and asked each participant to participate in a 60-minute focus group session after all participants 
had had access to the HRVB device for 7 weeks. 
During the initial study visit, the PI gathered demographic data, asked about exercise 
habits, and gave each participant an emWave2 HRVB device, which included the PPG and 
charger. The PI provided verbal and written instructions for HRVB use, and a practice plan for 
home implementation. Each participant practiced HRVB for 20 minutes with the device during 





Lehrer et al. (20), participants were instructed to practice HRVB using the emWave2 at home 
twice-daily for 20 minutes. The participants were given a phone number to call if they had any 
difficulty with the device or the practice schedule, or if they experienced other urgent concerns. 
During each visit the PI coached the participant to breath in a resonant pattern that 
increased HRC and changed the coherence level indicator on the emWave2 from red (low 
coherence), to blue (medium coherence/improving), to green (high coherence/optimal). 
Participants were coached to breathe at the green light level as long as possible during each 20-
minute practice session. Each visit, the PI downloaded data from the emWave2 and reviewed the 
practice frequency, length of practice sessions, and HRC levels with each participant. The PI 
discussed any problems with device and tried to resolve any difficulties the participant 
encountered. The PI also discussed strategies to adhere to the practice protocol and encouraged 
the participants to continue to practice. 
Focus Group Conduct 
To address aims 2 and 3, the PI conducted a 60-minute post-intervention focus group 
session after participants had access to the emWave2 device for 7 weeks. Before the initiation of 
the focus group, the PI consulted researchers with experience in focus group mediation and 
chronic pain management. The focus group, moderated by the PI, took place at the VA primary 
care clinic, where all study visits were also conducted. All study participants (n=10) were invited 
to participate; seven participants attended the discussion. Two of the seven participants arrived 
20 minutes after the start of the session.  
All focus groups participants consented to participation before attending the session. The 
focus group started with a short introduction, as well as reminders of participant confidentiality, 





meeting. We informed the participants that the meeting was being audio recorded and would be 
transcribed verbatim for data analysis. A predetermined set of open-ended questions guided the 
meeting; the questions were designed to elicit qualitative information about the participants’ 
ability to adhere to the HRVB protocol, as well as the acceptability of the intervention as a 
treatment for FM-related symptoms. We also asked open-ended questions about changes in pain 
severity and FM-related symptoms to explore the initial signal of efficacy of HRVB. We 
explored the hypothesis that self-directed, self-managed PSI such as HRVB would improve 
cognitive performance outcomes for QOL and functional status (26, 30). 
Data Analysis 
 We assessed the feasibility of recruitment of Veterans with FM by tabulating the 
responses to the study advertisement and study enrollment figures. Additionally, we evaluated 
the frequency of respondents which met exclusion criteria. We assessed individual attendance 
rates as well as the number of participants which attended the focus group session to evaluate 
retention.  
The author organized the data for content analysis using manifest and latent analysis (36) 
for the identification of themes regarding feasibility and acceptability. To increase data validity, 
a highly experienced qualitative researcher performed an independent analysis and discussed the 
results with the PI to obtain a consensus (36). We labeled the data with codes and categorized 
them into themes (36, 37).  
Feasibility was defined as participants’ ability to operate the emWave2 as well as 
implement follow the prescribed intervention protocol. With regard to the theoretical framework, 
when individuals can implement the practice of HRVB, they are able to attain the established 





(26). We defined acceptability as the participants’ self-reported willingness to follow the practice 
protocol and self-reported physiological and psychological responses to the intervention. 
Individuals who interpret their own strengths and weaknesses to achieve a goal are more 
successful with PSE enhancing interventions like HRVB (26). 
Results 
Recruitment/Retention 
After three weeks of advertising, 13 individuals from the VA primary care and mental 
health clinics expressed interest. One respondent was not a Veteran; he was given the flyer by a 
Veteran who saw it in the lobby. One respondent could not commit to the weekly visits because 
of her full-time work schedule, and another respondent did not meet the eligibility requirements 
because he was being treated with a cardiac regulating medication. The remaining respondents, 
n=10, met eligibility requirements, provided informed consent, and were enrolled in the study. 
Eight of the ten participants attended 75-100% of the study visits (Table 1), and seven of 
ten attended the end of study focus group session. Veteran 6 (Table 1) did not return to the clinic 
after week 3. The PI called Veteran 6 each week to remind him of his appointment, and each 
time he stated he would come to the following visit. The PI asked Veteran 6 why he missed the 
previous visit, and he reported he became distracted and forgot, had unexpected family 
obligations, and the last two visits he reported either he, his wife, or his children were ill with 
upper respiratory symptoms. Veteran 6 lives 1.5 hours away from the clinic, which may have 
also been a contributing factor. Veteran 5 (Table 1) attended the first two visits and the 7th visit. 
The PI called her the day before each scheduled visit to remind her; however, she never 
answered the phone, and the PI was not able to leave a message for her. During her visits, the PI 





continued to encourage her to practice her resonant breathing between visits. The participant 
dropped off her device at the front desk of the clinic at the end of the study, and she did not 
attend visit 8 or the focus group. Data from her device indicated she practiced 27 of the 49 days 
(55.1%) of the study. 
Table 1. Weekly attendance rate 
            Weeks    
 1 2 3 4 5 6 7 8 Freq % FG 
Veteran            
1 A  A A A A A A 7 87.5 A 
2 A A A A A A A A 8 100  
3 A A A A  A A  6 75 A 
4 A   A A A A A 6 75 A 
5 A A     A  3 37.5  
6 A  A      2 25  
7 A  A A   A A 5 62.5 A 
8 A  A A A A A A 7 87.5 A 
9 A A A A A A A  7 87.5 A 
10 A A A  A A A A 7 87.5 A 
Key: A = attendance 
         FG = focus group 
 
Participant Characteristics  
We enrolled 7 women between the age of 33 and 68 years (mean=52) and 3 men between 
the ages of 33 and 54 years (mean =47). The participants were white (n=5) or African American 
(n=4). One participant self-selected Hispanic ethnicity yet declined to self-select race. All had at 
least some higher education (Table 2). Only 3 participants were employed. All participants had a 
mental health diagnosis of depression (n=6), anxiety (n=2), and/or post-traumatic stress disorder 
(PTSD) (n=4). Most (70%) were married. Four of the seven women reported exercising 
aerobically, with strength training and/or stretching (Table 3). One of the three men reported 
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Feasibility of Prescribed HRVB Protocol 
 To address the feasibility of the HRVB protocol, the facilitator asked participants if they 
had difficulty following the home practice schedule of 20 minutes twice daily, and if so, what the 
difficulties were. The resulting data were coded as implementation and adherence.  
Implementation 
 A common barrier to implementation of the protocol was difficulty finding time to 
practice. Three participants work full time jobs; one participant cares for her husband who is 
receiving chemotherapy and she drives him to his appointments. Another participant is a 
caregiver to her disabled husband and actively helps care for her young grandchildren. These 
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these barriers and helped the participant identify strategies to overcome these barriers. Some 
strategies were setting aside 20 minutes before the children got up in the morning, or before they 
came home from school, using lunch break to sit in a quiet area of the building or in the car to 
practice. In the case of the participant’s spouse was receiving chemotherapy, the PI suggested 
practicing in a quiet place while she was waiting for him to complete his treatment. Three 
participants were strictly adhering to a stressful schedule and preferred to practice when it was 
convenient. The following are salient responses: 
Veteran 7 stated, “I stressed out over it, because my work schedule's weird, so 
trying to get it on a consistent schedule was difficult and then, I would get frustrated 
with myself, because I didn't do it like I was supposed to.” 
 
Veteran 1 reported, “I found it a lot easier for me to just use it anytime it was 
convenient for me, as I was driving, I was going for appointment, I was waiting, or 
whatever the case may be, I just made it work with my schedule, because if I tried 
to just do it twice a day at a given time, it just didn't really work for me.” 
 
Veteran 3 summed it up by stating, “We are all too busy, everybody’s always too 
busy.” 
 
 Another identified barrier to protocol implementation was difficulty operating the device. 
The most common problem reported was with the PPG. Participants had difficulty getting a 
pulse when they clipped the PPG to their earlobe. 
Veteran 3 reported, “It wouldn't work on my finger. Periodically, it worked on different 
places on my ears.”  
 
A key feature of the emWave2 is that the device shuts off automatically if there is no pulse 
reading. Some of the participants reported frustration about the device shutting off during the 
individual study sessions. These frustrations were reiterated during the focus group session. 
Veteran 4 stated, “It would kill my ears, I had to use my finger, and it wouldn’t read 
the pulse all of the time.” 
 







The PI addressed these difficulties during the study sessions. The researcher assisted the affected 
participants by trying different areas of the ear, and by attaching the PPG to the fingertips. 
Two participants reported it would have been helpful to have a resource video to refer to 
for technical difficulties. One participant was able to find a freely available video online for the 
emWave2 and was able to alleviate the problem of finding a pulse with the PPG. 
We identified implementation facilitators during the focus group session and during 
individual visits with the PI. Veteran 7 and Veteran 2 implemented the practice protocol because 
they believe biofeedback is an acceptable treatment alternative to medications and other more 
invasive treatment options they have tried in the past. Veteran 9 reported he had heard of the 
psychological and physiological benefits of HRVB in the media and was anxious to start the 
prescribed protocol. 
Veteran 5 reported she was able to implement the intervention if she did not try to follow 
a schedule.  She stated it was easier for her to practice at her convenience, like when she was 
driving on her way to appointment or waiting in an office or waiting room. The PI advised the 
Veteran not to practice HRVB while driving because the practice of HRVB may detract her from 
driving safely. She verbalized understanding and assured the PI she would refrain from such 
behavior in the future. 
Adherence 
 Four of the participants reported they tried to make up for missed practice sessions by 
practicing for longer than the prescribed 20-minute sessions or practicing extra sessions when 
they had time.  
Veteran 10 reported, “I missed some days, too, but when I do remember, I always 
do like three times because I actually need to bring my heart rate down back to 






Veteran 3 stated, “If once a day then for an hour, twice a day most times.” 
 
One participant reported he followed the practice protocol because he had watched a 
video about the physiological changes that occurs when one engages with HRVB. Some 
participants reported the visual feedback system of the emWave2, the HRC indicator light 
changing from red (low HRC) to blue (moderate HRC) and to green (optimal HRC) (38), was a 
beneficial factor in their protocol adherence. 
Veteran 1 reported, “I thought the lights were helpful, when you were in bed 
breathing you can see a difference. You didn’t want it to stay red. It would gradually 
go to blue and then green. If you stayed in the green you would hear pop pop pop 
and I know I am doing it right.” 
 
The study team identified some barriers to adherence. Participants reported 
inconveniences of carrying the emWave2 with them. They reported they may have been more 
compliant with the protocol if they could have practiced on their cell phones, which they carry 
everywhere. Veteran 10 reported, “I don’t see it, I don’t remember.” One participant was 
bothered by the beeping sounds emitted from the device and curtailed the practice time to avoid 
the sounds. The “beeping” problem was resolved during the next clinic visit after receiving 
guidance about how to control the audio features. 
Lastly, one Veteran reported “chest pain” if she practiced for the prescribed 20 minutes, 
resulting in less time spent during each practice session as well as fewer practice sessions during 
the week. Her reported chest pain was evaluated by the PI during the individual clinic visit and 
determined to be chest wall pain and not cardiac pain. Participants were instructed to seek 
emergency medical care for any urgent cardiac-related symptoms. Her symptoms gradually 
improved from week to week, and by the end of the 8-week study, she was able to practice for 





Acceptability of the intervention 
The facilitator asked participants if the intervention helped with pain or other FM-related 
symptoms like sleep, depression, anxiety, or memory. One of the foundations of PSE-enhancing 
interventions is individual interpretation of inferences from physiological and psychological 
responses that indicate personal strengths and vulnerabilities to reach goals of the intervention 
(26). The discussion data were coded as self-efficacy of HRVB. Results related to self-efficacy 
of pain symptoms were mixed: 2 of 7 reported some relief in pain, 2 of 7 reported they were 
unsure if they experienced pain relief, and 1 of 7 reported no pain relief.  
Veteran 10 reported, “So, I had to use it to calm me down too, because I realized 
with it, it also by calming me down and getting my breathing under control, it would 
help with the pain too, because last time, I'd been in pain all the time, so it kind of 
helped.” 
 
Veteran 4 stated, “It's hard to tell because I still get injections in my back. I get 
infusions once a month because I've got multiple things going on, so it's really hard 
to tell. It was relaxing.” 
 
Veteran 4 added, “Yeah, and so yeah it helped with the muscle spasms and all that, 
but as far as the pain, I live with it.” 
 
Participants reported changes in other FM-related symptoms, such as breathing, 
relaxation, cognition, and sleep. Participants recognized that when they engaged in the resonant 
breathing, they experienced relaxation and decreased anxiety, which directly impacted pain 
tolerance.  
Veteran 1 shared, “The other thing I found was you hear a lot about how your body 
naturally heals itself, but with this machine, you also realize how the body impacts 
you as a person and what you do to help your body heal itself can make a difference, 
because when I used the machine, I notice a lot of things about my own body, how 
my body reacts to how I breathe, how I feel, after the machine and even before the 
machine, because it made a difference in how I was feeling." 
 
Veteran 1 added, “It made a difference in my pain level too with my breathing, and 
I've always practiced breathing, but I've never practiced it on a machine where I 





were happening at different times and that's when I realized too, use the machine at 
night and then, in the morning. Sometimes, at night, during the day, depending on 
what I'm doing and when I'm having real, I just want to slap somebody ... and 
noticed a difference in how I was feeling and what I was doing when I stopped and 
used the machine.” 
 
Veteran 9 stated, “Especially when I did it in the evening, it also helped the sleeping 
tremendously. Because you were getting into a relaxed state, which does help you 
sleep.” 
 
They were aware that mental distraction increased a sense of calmness and self-corrected 
when the indicator lights turned red. 
Veteran 8 reported, “So, just in terms of the thought distraction helps overall 
calmness feeling and then, but when it did go red, it made me more aware of what 
I was feeling at the time physically and mentally, and it was kind of an, ‘Oh,’ it 
helped me make those connections.”  
 
We also evaluated intervention acceptability by asking the participants if they would 
recommend HRVB to other Veterans with FM. The responses were a unanimous yes. They felt 
HRVB was a good alternative to medication and an option when all else has failed. 
Veteran 9 reported, “I think there's a lot to be said with biofeedback, especially 
when you've tried everything else.” 
 




 HRVB is a promising self-treatment option to improve the FM-related symptoms like 
pain, mental fog, anxiety, and sleep disturbance, as well as functional status and QOL (13, 21, 
24). Lehrer et al. (20) determined individuals cannot simply achieve HRC by slowing their 
breathing rate and thus developed an HRVB training protocol to optimize resonant breathing to 
reach optimal HRC. However, we failed to find any research to support the feasibility or 





Core elements of self-management skills include decision making, resource utilization, 
and problem solving (26). When participants were instructed to practice HRVB twice daily for 
20 minutes, they had to choose to make time to practice and to avail themselves of the resources 
provided, e.g., by calling the PI for any difficulties and/or discussing barriers to the practice 
protocol, and with the PI’s guidance, problem solving any difficulties with the device.  
Individual perceived self-efficacy (PSE) beliefs are not only developed through 
performing an activity (26). PSE is also developed by observing others successfully 
understanding an activity, and by social or verbal persuasion that one can be successful (26), 
received either from peers or healthcare providers. Our study participants did not have an 
opportunity to observe others practice HRVB, and they only received encouragement from the PI 
during the in-person session. In future trials, to help improve participant self-efficacy, we 
recommend providing participants with a calendar, negotiating an acceptable schedule during the 
initial study visit, and reviewing the schedule for adjustments as the individual encounters 
implementation obstacles. We also suggest conducting multiple focus groups during the study to 
provide opportunities for participants to discuss implementation barriers with other participants 
as well as observe helpful techniques.  
Additional core elements of self-management skills include decision making, resource 
utilization, and problem solving (26). When the Veterans encountered difficulties with the PPG, 
they became frustrated and practiced less frequently. Participants were given a phone number to 
contact the PI and instructed to call at any time between the hours of 0700 and 2100. No 
participants called the PI for assistance. In future studies we may include an instructional video 
for individual reference. Future study protocols also may include instructions on how to access 





emWave2, have an online forum for technological problems (39). Some Veterans reported the 
device itself was inconvenient because it was another object to carry with them. HeartMath® has 
software for mobile phones that operates similarly to the emWave2 device (40). Future trials may 
consider utilizing HRVB software that can be downloaded onto a mobile phone.  
FM-related symptoms can vary from day to day, depending upon elements such as sleep, 
stress, or ambient temperature, potentially leading to frustration and feelings of lack of control 
over symptom self-management (2); those factors may contribute to skepticism of treatment 
recommendations (4). Gaining control with activities like HRVB may maximize symptom 
management (26). Although Veterans did not report complete pain relief, there was some 
improvement in pain and there was a consensus of overall improvement in other FM-related 
symptoms such as sleep, cognition, and relaxation. Ease of relaxed breathing, improvements in 
sleep, increased calmness, and improved cognition were all interrelated and have been 
demonstrated in other studies to improve QOL in individuals with FM (1, 6, 41). In their HRVB 
study for FM, Hassett et al. (24) reported similar results to ours: an improvement in functional 
status, relief of FM-related symptoms, and improvement in QOL. 
In our study there was an isolated case of chest wall pain associated with the resonant 
breathing of HRVB. We did not discover any complaints of chest wall pain in earlier studies of 
HRVB to treat FM-related pain or chronic musculoskeletal pain (23, 24, 27, 35, 42, 43). 
However, this should be addressed and reported if discovered in future trials. Researchers should 
also stress the importance safely practicing HRVB, like while driving or conducting activities 








 HRVB is a promising treatment option for FM-related symptoms. Limitations of this 
study include the small sample size. Additionally, the PI led a single focus group session. The 
participants were asked to recall events and experiences over an eight-week period.   
Our findings indicate that there were difficulties operating the device and scheduling 
challenges that interfered with implementation of the intervention. Future trials may be able to 
prevent some of the equipment difficulties with clearer instructions and participant access to the 
developer’s website. Although our qualitative analysis suggests HRVB is an acceptable 
treatment for Veterans with FM, more detailed interviews from a larger sample are needed. 
Adding individual interviews at several points throughout the study may provide deeper insight 
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 As the incidence rates of fibromyalgia (FM) rise in U.S. Veterans, (1) health care 
providers are challenged to find safe, effective, and acceptable treatment options. FM-
related symptoms are complex (2-4), and treatment must be multi-focal (5). Heart rate 
variability biofeedback (HRVB) is a self-management strategy (6) that has the potential 
to improve emotion regulation, stress resistance (7-9), and quality of life (9, 10) for 
individuals with FM. Repeated sessions of HRVB can optimize stress resistance, 
decrease pain, and increase overall well-being (6). The overarching question of whether 
HRVB is a feasible and acceptable treatment for Veterans with FM-related chronic pain 
is covered in three manuscripts. The first manuscript is an integrative literature review 
examining the relationship between HRVB and FM-related chronic pain. The second and 
third manuscripts report the quantitative and qualitative findings of the feasibility and 
acceptability study we conducted of HRVB to treat FM-related chronic pain.  
In the first manuscript, we examined the relationship between HRVB and FM-
related pain through the lens of the TSSM. We reviewed five studies that reported the 
results of HRVB as a treatment for chronic musculoskeletal pain (7, 8, 11-13) and one 
study investigating HRVB to treat FM-related chronic pain (9). All six authors reported 
an overall improvement in chronic pain (7-9, 11-13); however, only Hassett et al. (9), 
Hallman et al. (8) and Soer et al. (11) reported changes in functional status and quality of 
life. Hassett et al. (9) reported improved functional status and quality of life after HRVB 
from results of the Fibromyalgia Impact Questionnaire (FIQ). Soer et al. (11) and 
Hallman et al. (8) reported improvements in vitality as well as functional and social status 
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after HRVB from the Short Form Health Survey (SF-36). However, these were pilot 
studies that were not designed to test a hypothesis (14). HRVB practice protocols 
reported in manuscript 1 were inconsistent, so it was difficult to determine if the 
researchers implemented Lehrer’s (15) protocols.  
Additionally, we were not able to determine if outcomes of functional status and 
quality of life were related to the intervention. We did not identify any studies that 
addressed individual adherence to the practice protocols of HRVB as an intervention to 
treat FM-related chronic pain. Finally, we did not locate any qualitative studies that 
examined participant acceptability of HRVB as a treatment for FM-related pain. 
Manuscript two reported the feasibility and adherence to a recommended HRVB 
protocol. We enrolled 10 Veterans to evaluate feasibility and adherence to a twice a day, 
twenty-minute HRVB practice protocol on the emWave2 device for eight weeks. The 
Veterans in our study did not adhere to the recommended twice-daily practice protocol. 
Veterans cited scheduling difficulties related to jobs, family care obligations, and 
otherwise busy schedules as barriers to the practice schedule. However, the Veterans 
practiced for the recommended 20 minutes whenever they made the time for practice. We 
examined earlier studies but did not locate any studies that allowed participants to take 
the HRVB device for home practice.  
In manuscript two we also reported data from the FIQ and noted that overall 
participants did not reports any significant change in FM-related symptoms like pain, 
fatigue, depression or memory problems. However, consistent with findings reported by 
Hassett et al. (9) the participants did report a slight improvement in functional status, like 
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being able to complete some household chores, walking for 20 minutes or climbing one 
flight of stairs, and an overall improvement in the quality of life post-intervention.  
As stated earlier, we did not identify any qualitative studies of HRVB to treat FM-
related symptoms. To address this gap in the literature, we conducted a focus group post-
intervention seeking Veterans’ insights into the twice-daily 20-minute HRVB protocol 
and reported the results in manuscript 3. While we were able to determine the Veterans 
did not practice twice daily as instructed, it was valuable to discover why they did not 
practice. The Veterans reported family obligations, work schedules, and difficulties 
adhering to a new habit as barriers to practice. The participants also reported some 
difficulties managing the settings on the HRVB device that interfered with the practice 
schedule. Although not reflected in the answers reported on the FIQ, during the focus 
group sessions, the Veterans reported the realization of a connection between HRVB and 
improved FM-related symptoms like sleep and anxiety. Additionally, the participants in 
the focus group reported decreased pain levels; however, this was not reflected on the 
quantitative pain scales they completed at each individual visit. The Veterans also viewed 
the visual feedback of the emWave2 as helpful in maintaining the positive effects of 
HRVB. This insight will be helpful when we develop future HRVB study protocols. 
 There were several limitations to this dissertation. This study was small (n=10) 
and did not have a control group. Confounding variables such as other pain treatment 
modalities may have influenced the outcomes of this study. Although all participants met 
inclusion criteria, 50% (n=5) of the study participants were known to the PI through prior 
care in the Veterans Administration (VA) pain clinic; thus, there was a risk of selection 
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bias. A larger randomized controlled trial of participants recruited from multiple clinics 
may minimize these limitations.  
This PI had limited experience in conducting a focus group. After review of the 
focus group transcript and discussions with a seasoned qualitative researcher, we 
identified several limitations. Although the PI kept to the pre-determined focus group 
script, she did not recognize several opportunities to obtain deeper insight into the 
Veterans’ experiences with the intervention. If the PI had ventured from the script and 
asked for further clarifications to comments by the participants, she may have gained 
richer valuable data about the barriers to the practice protocol as well as insights about 
participant self-efficacy of the benefits of HRVB. Additionally, the PI only conducted 
one focus group at the end of the study. When the PI was developing the study protocol, 
she believed one post-intervention session would be enough to gain insight into the 
Veterans’ experiences with HRVB. However, the participants were asked to recall 
insights into interventions over eight weeks, and the PI now recognizes that participant 
recall may have been improved with additional meetings at various points throughout the 
study. 
 None of the HRVB studies we identified in our integrative literature review 
(manuscript 1) applied a theoretical or conceptual framework. Future research about 
biofeedback to treat FM-related symptoms should use a theoretical framework that 
addresses self-management and self-efficacy to increase treatment adherence and 
optimize performance outcomes such as functional status and quality of life. This 
dissertation study was guided by the central tenant of TSSM, that implementation of self-
management interventions improves performance outcomes like quality of life and 
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functional status. An important construct of TSSM to consider is that activities such as 
social and verbal persuasions from peers and observing others perform the activity 
successfully can assist individuals to identify their strengths and vulnerabilities to achieve 
their goal (16). Peer mentorship or group visits may be useful in future studies.  
 I want to continue my investigation of HRVB as a treatment option for Veterans 
with FM. The VA is committed to developing and integrating non-pharmacological 
modalities into individual pain care plans. My goal is to conduct a pilot study of HRVB 
for the treatment of chronic pain in Veterans with FM. I will update my integrative 
literature review with any new studies conducted to treat FM with HRVB. I will review 
the findings of this study to develop a study protocol that may minimize some of the 
limitations identified. HRVB is being used within the VA to treat post-traumatic stress 
disorder, so I will communicate with the champions of HRVB, and discuss strategies for 
obtaining the HRVB devices, planning a study protocol, and recruitment strategies. I plan 
to apply for the VA Nursing Research Initiative grant and work closely with pain team 
members and seasoned researchers.  
Implications 
 The results of this dissertation have several implications for health care provider 
education, clinical practice, and future research for FM-related chronic pain treatment.  
This dissertation introduces medical providers to an alternative to pharmacological 
treatment for FM-related chronic pain that is safe and accepted by individuals with FM. 
The information provided in the integrative literature review (manuscript 1) will inform 
health care providers of the gap in the literature concerning the feasibility of following 
the recommended HRVB protocol and lack of studies of HRVB as a treatment option for 
97 
 
FM-related pain. The quantitative study (manuscript 2) informs health care practitioners 
who plan to implement HRVB into their pain treatment plan that a twice-daily 20-minute 
practice protocol is not feasible for individuals with FM and may require adjustment. 
Although this quantitative study (manuscript 2) was not designed to provide inferential 
statistics, we did recognize a suggestion of individual improvement in functional status 
and quality of life post-intervention. Results of the qualitative study (manuscript 3) will 
inform practitioners that individuals reported difficulties following the treatment protocol 
because of scheduling and family obligations. Health care providers can use this 
information to anticipate barriers to the prescribed protocol and help patients identify pre-
determined scheduling conflicts and develop an individual schedule that is easy to 
maintain. Health care providers will learn that although the participants were unable to 
follow the recommended protocol, they acknowledged the positive physiological and 
psychological effects.  
The implementation of HRVB for FM-related chronic pain follows current 
treatment guidelines that prioritize nonpharmacological treatments based on the 
biopsychosocial model (5, 17). The emWave2 device is affordable and readily available 
on the general market (18). With this novel approach, health care providers may 
empower individuals to self-manage their FM-related chronic pain. Additionally, FM 
patients are often skeptical of pharmacological treatments for their symptoms (19) and 
are more receptive to holistic providers (20) that offer treatments like HRVB.  
Future research 
The integrative literature review (manuscript 1) demonstrates the need for 
additional research investigating the use of HRVB as an acceptable treatment option to 
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manage the chronic pain associated with FM. Additionally, we were unable to locate 
prior studies that address the feasibility of individuals with FM to adhere to the 
recommended HRVB protocol. Although our quantitative study (manuscript 2) results 
suggested an improvement in functional status and quality of life in individuals with FM, 
randomized controlled trials that are adequately powered to determine HRVB outcomes 
are needed. The integrative literature review (manuscript 1) also supports the need for 
qualitative studies that will investigate individual insight into this novel approach, so that 
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Focus group questions for study reported in manuscript 3 
 
Focus Group Questions 
 
Set 1 Questions  
1. How often did you use the device? 
2. Did you look forward to using it? 
3. Do you think if helped your pain? 
4. Did it help anything else besides pain? 
5. Was there a downside to using it? 
6. Do you think there could be a better way of teaching this to people? 
 
Set 2 Questions  
7. Did you have any technical difficulties? If so, what were they? How did they get 
resolved? Did the problem(s) change your practice schedule?  
8. Were you frustrated with the device? 
9. Did you have any difficulty following the home practice schedule? If so, what were 
they? What kind of changes did you make to the home practice schedule? 
10. If you could talk to other Veterans with FM, what would you tell him/her about your 




Demographics questionnaire for study reported in manuscripts 2 & 3 
 
GENERAL BACKGROUND INFORMATION 
 
1. Today’s date: __/__/___ (month/day/year) 
 
2. Age: ____ 
 
3. Gender: (check one) 
1. __Female   
2. __ Male 
 
4. Race (check all that apply) 
1. __White      
2. __ Black or African American    
3. __ American Indian or Alaskan Native 
4. __ Asian 
5. __ Native Hawaiian or Other Pacific Islander 
 
5. Ethnicity 
1. __ Hispanic or Latino 
 
6. Highest level of school completed (check one) 
1. __ High School graduate (includes GED)   
2. __ Partial college or vocational training 
3. __ College or university graduate 
4. __ Graduate professional training 
 
7. Employment status 
1. __ Unemployed 
2. __ Seeking employment  
3. __ Medically disabled, unable to work 
4. __ Medically disabled, working    
5. __ Part-time employed   
6. __ Full-time employed 
4. __ Retired 
 
8. Mental health history (check all that apply) 
1. __ Depression      
2. __ Anxiety disorder     
3. __ PTSD 
4. __ Panic disorder 
5. __ Other, please specify (_________________________________) 
 
9. Marital status (check all that apply) 
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1. __ Never married     
2. __ Married     
3. __ Separated 
4. __ Divorced 
5. __ Widowed 
 
10. How many days per week do you walk, use elliptical machine, bike, swim, dance 
or perform other movement activities for at least 30 minutes? (check one) 
1. __ Never      
2. __ 1-2 times a week     
3. __ 3-4 times a week 
4. __ 5-6 times a week 
5. __ 7 times a week 
 
11. How many days per week do you use any weights to strengthen your muscles for 
at least 15 minutes? (check one) 
1. __ Never      
2. __ 1-2 times a week     
3. __ 3-4 times a week 
4. __ 5-6 times a week 
5. __ 7 times a week 
 
12. How many days per week do you stretch your muscles for at least 15 minutes?  
(check one) 
1. __ Never      
2. __ 1-2 times a week     
3. __ 3-4 times a week 
4. __ 5-6 times a week 









We would like you to indicate below how much you believe, right now, that the treatment 
you are receiving will help reduce your pain. Belief usually has two aspects to it: 1) what 
one thinks will happy and 2) what one feels will happen. Sometimes these are similar; 
sometimes they are different. Please answer the questions below. In the first set, answer 





1. At this point, how logical does the biofeedback treatment offered to you seem? 
1 2 3 4 5 6 7 8 9 
not at all logical   somewhat logical   very logical 
 
 
2. At this point, how successfully do you think this biofeedback treatment will be in 
reducing your pain? 
1 2 3 4 5 6 7 8 9 
not at all useful   somewhat useful   very useful 
 
 
3. How confident would you be in recommending this biofeedback treatment to a friend 
who experiences similar problems? 
1 2 3 4 5 6 7 8 9 
not at all confident   somewhat confident   very confident 
 
 
4. By the end of the biofeedback treatment period, how much improvement in your pain 
do you think will occur? 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
 
Set II 
For this set, close your eyes for a few moments, and try to identify what you really feel 
about the treatment and its likely success. Then answer the following questions. 
 
1. At this point, how much do you really feel that the biofeedback treatment will help you 
to reduce your pain? 
1 2 3 4 5 6 7 8 9 
not at all   somewhat   very much 
 
2. By the end of the biofeedback treatment period, how much improvement in your pain 
do you really feel will occur? 






Fibromyalgia impact questionnaire for study reported in manuscript 2  
REVISED FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQR)  
Unique Identifier:                                
Age:   
Duration of FM symptoms (years) :     Time since FM was first diagnosed (years):  
Directions: For each of the following 9 questions check the box that best indicates how much 
your fibromyalgia made it difficult to perform each of the following activities during the past 7 
days. If you did not perform a particular activity in the last 7 days, rate the difficulty for the last 
time you performed the activity.  If you can’t perform an activity, check the last box.  
Brush or comb your 
hair   No difficulty      □ □ □ □ □ □ □ □ □  □ □      Very 
difficult  
Walk continuously 
for 20 minutes   No difficulty      □ □ □ □ □ □ □ □ □  □ □      Very 
difficult  
Prepare a 
homemade meal   No difficulty      □ □ □ □ □ □ □ □ □  □ □      Very 
difficult  
Vacuum, scrub or 
sweep floors   No difficulty      □ □ □ □ □ □ □ □ □  □ □      Very 
difficult  
Lift and carry a bag 
full of groceries    No difficulty      □ □ □ □ □ □ □ □ □  □ □      Very 
difficult  
Climb one flight of 
stairs    No difficulty      □ □ □ □ □ □ □ □ □  □ □      Very 
difficult  
Change bed sheets   No difficulty      □ □ □ □ □ □ □ □ □  □ □      Very 
difficult  
Sit in a chair for 45 
minutes    No difficulty      □ □ □ □ □ □ □ □ □  □ □      Very 
difficult  
Go shopping for 
groceries   No difficulty      □ □ □ □ □ □ □ □ □  □ □      Very 
difficult  
  
  Sub-total (for internal use only)   
 
Directions: For each of the following 2 questions, check the box that best describes the 
overall  impact of your fibromyalgia over the last 7 days:   
Fibromyalgia prevented me from 
accomplishing goals for the 
week  
Never  □ □ □ □ □ □ □ □ □  □ □     
Always  
I was completely overwhelmed 
by my fibromyalgia symptoms  






 Sub-total (for internal use only) 
FIQR © Robert M Bennett & Ronald Friend, 2009. All Rights Reserved.  
FIQR – USA/English – Original version  
FIQR_AU1.0_eng-USori   
Directions: For each of the following 10 questions, select the box that best indicates your 
intensity of these common fibromyalgia symptoms over the past 7 days  
Please rate 
your level 








of energy  
  
Lots of energy    □ □ □ □ □ □ □ □ □  □ □       No energy  
Please rate 
your  level 
of stiffness  
  






Awoke well rested          □ □ □ □ □ □ □ □ □  □ □      

















of anxiety   
  
  





to touch  
  
  






















No sensitivity     □ □ □ □ □ □ □ □ □  □ □      Extreme 
sensitivity  
  





 FIQR TOTAL (for internal use only)   
FIQR © Robert M Bennett & Ronald Friend, 2009. All Rights Reserved.  






Short-form McGill pain questionnaire for study reported in manuscript 2 
I. Short-Form McGill Pain 
Questionnaire 
 
A. PLEASE DESCRIBE YOUR PAIN DURING THE LAST WEEK. (Check off one box per line.) 
 
 
None Mild Moderate Severe 
1. Throbbing 0  1  2  3  
2. Shooting 0  1  2  3  
3. Stabbing 0  1  2  3  
4. Sharp 0  1  2  3  
5. Cramping 0  1  2  3  
6. Gnawing 0  1  2  3  
7. Hot-burning 0  1  2  3  
8. Aching 0  1  2  3  
9. Heavy (like a 
weight) 
0  1  2  3  
10. Tender 0  1  2  3  
11. Splitting 0  1  2  3  
12. Tiring-Exhausting 0  1  2  3  
13. Sickening 0  1  2  3  
14. Fear-causing 0  1  2  3  
15. Punishing-Cruel 0  1  2  3  
 
 
II. B. PLEASE RATE YOUR PAIN DURING THE LAST WEEK. 
The following line represents pain of increasing intensity from “no pain” to “worst possible  
pain”. Place a vertical mark (|) across the line in the position that best describes your  
pain during the last week. 
 


























III. C. CURRENT PAIN INTENSITY 
0   No pain 
1   Mild  
2   Discomforting 
3   Distressing 
4   Horrible 
5   Excruciating 
 
 Copyright R. Melzack, 1970, 1987 
 
 
Questionnaire Developed by: Ronald Melzack 
 
